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The National Institute of Allergy and Infectious
Diseases (NIAID) has long recognized that minority
populations bear a disproportionate burden of
sickness and disease in the United States.
Differences in racial and ethnic backgrounds can
affect susceptibility to infectious and immunologic
diseases, including acquired immunodeficiency
syndrome (AIDS), asthma, sexually transmitted
infections, and kidney disease.  Moreover, minority
populations often do not fully benefit from research
advances that have helped improve the health of
other Americans.  
For more than 50 years, NIAID has progressed in
understanding, treating, and preventing infectious
and immunologic diseases known to occur
disparately in minority populations.  As outlined in
its Strategic Plan for Addressing Health Disparities,
NIAID continues to prioritize basic, clinical, and
epidemiological research in addressing the health
disparities in minority populations.  Specifically,
NIAID supports efforts to increase the participation
of minority scientists in its research, increase the
participation of the minority community in clinical
research, and design targeted outreach activities for
minority communities that communicate research
developments and health risk.  
Asthma and Allergic Diseases
Asthma morbidity and mortality have been
increasing in the United States for the past 15 years
and are particularly high among poor, African
American, inner-city residents.  For more than a
decade, improving the management of asthma in
children has remained a high priority for NIAID.
Preliminary results from the Inner-City Asthma
Study (1996–2001), co-sponsored by the National
Institute of Environmental Health Sciences, indicate
that physician education and an extensive
environmental intervention can successfully reduce
asthma symptoms among inner-city children and
can continue to reduce symptoms 1 year after
intervention.  The Inner-City Asthma Consortium
(ICAC), established by NIAID in 2002, was created
to evaluate the safety and effectiveness of promising
immune-based asthma treatments developed to
reduce asthma severity and prevent disease onset in
inner-city children.  ICAC will conduct research to
determine the mechanisms of action of immune-
based therapies; develop and validate biomarkers to
measure disease stage, progression, and therapeutic
effect; and understand the immunopathogenesis of
asthma in inner-city children.
NIAID’s Asthma and Allergic Diseases Research
Centers program is the cornerstone of the
pathobiology component of NIAID asthma and
allergy research.  This national network of centers
conducts basic and clinical research on the
mechanisms, diagnosis, treatment, and prevention of
asthma and allergic diseases.  In 2003, NIAID
funded 4 Asthma and Allergic Diseases Research
Centers, bringing the total number of centers to 13.  
In 2003, NIAID requested applications for research
projects aimed at understanding the early life
changes in immune function that led to the
development of asthma (RFA-AI-03-041 “Immune
System Development and the Genesis of Asthma”).
The Immune System Development and the Genesis
of Asthma program will be launched in 2004 and
will be co-funded by the National Heart, Lung, and
Blood Institute (NHLBI).  In response to provisions
in the Children’s Health Act of 2000 (P.L. 106-310),
NIAID participates in the Federal Liaison Group for
Asthma, a subcommittee of the National Asthma
Education and Prevention Program.
Autoimmune Diseases 
Collectively, autoimmune diseases afflict more than
5 percent of the U.S. population, and women are
more likely to suffer from an autoimmune disease
than men.  Several autoimmune diseases, such as
systemic lupus erythematosus (SLE) and
scleroderma, disproportionately affect minority
populations.  NIAID supports a broad portfolio of
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basic, preclinical, and clinical research aimed at
understanding the pathogenesis of autoimmune
diseases.  Research programs include the
Autoimmunity Centers of Excellence (ACE), the
Autoimmune Disease Prevention Centers, and
multidisciplinary research targeting the
identification, characterization, and definition of
gender-based differences in the immune response.
In 2003, ACE was renewed and expanded to
include nine separate institutions.  Trials for new
immunomodulatory interventions and studies of
mechanisms of action are being developed.  Centers
are co-sponsored by the National Institute of
Diabetes and Digestive and Kidney Diseases
(NIDDK) and the NIH Office of Research on
Women’s Health (ORWH).  In fiscal year (FY)
2003, Autoimmune Disease Prevention Centers
supported 14 pilot projects to test innovative
approaches that may lead to the development of
novel targets for disease prevention or assays for
biomarkers of disease progression.  The prevention
centers are co-sponsored by NIDDK, the National
Institute of Child Health and Human
Development, ORWH, and the Juvenile Diabetes
Research Foundation International (JDRF).  
NIAID continues to support the Immune Tolerance
Network (ITN).  Co-sponsored by the NIDDK and
JDRF, ITN is an international consortium of more
than 80 investigators throughout the United States,
Canada, and Europe dedicated to the clinical
evaluation of novel, tolerance-inducing therapies for
autoimmune diseases, asthma and allergic diseases,
as well as the development of tolerance-inducing
therapies to prevent the rejection of transplanted
organs, tissues, and cells.  NIAID supports the
Multiple Autoimmune Disease Genetics
Consortium (MADGC), a repository of genetic and
clinical data and materials from families in which
two or more individuals are affected by two or more
distinct autoimmune diseases.  MADGC has
enrolled more than 150 families since May 2000.
Established in FY 1998, NIAID continues to chair
the Autoimmune Diseases Coordinating Committee
(ADCC).  The ADCC Autoimmune Diseases
Research Plan was presented to Congress in 2002.  
Transplantation
Organ transplantation represents a health disparity
for African Americans and other minorities, who
receive fewer transplants than would be expected
from their representation on the transplant waiting
list.  NIAID supports a broad portfolio of research
to address immune-mediated graft rejection,
including basic research in transplantation
immunology, preclinical evaluation of new
therapies, and clinical trials of promising
therapeutic approaches to improve short- and long-
term graft survival.  In 2003, NIAID renewed the
Cooperative Clinical Trial in Pediatric
Transplantation (CCTPT) program.  CCTPT
supports multicenter clinical trials of novel
approaches to prevent acute and chronic graft
rejection in pediatric kidney transplantation,
evaluates modifications of immunosuppressive drug
regimens to mitigate unwanted side effects of
immunosuppression, and assesses pretransplant
immunotherapy to improve transplantation
outcomes.  NIAID’s Division of Allergy,
Immunology and Transplantation and NIAID’s
Division of AIDS launched a study on the
outcomes of kidney and liver transplantation for
HIV-positive (HIV+) patients in 2003.  The
primary aim of this prospective, multicenter cohort
study is to evaluate the safety and efficacy of solid
organ transplantation in HIV+ patients who
undergo kidney or liver transplantation.  
In 2001, NIAID and NHLBI renewed the
Immunopathogenesis of Chronic Graft Rejection
Program, designed to enhance knowledge of chronic
graft failure.  NIAID, in collaboration with
NIDDK, supports the Non-Human Primate
Immune Tolerance Cooperative Study Group to
evaluate the safety and efficacy of novel tolerogenic
regimens in preclinical animal models of kidney and
islet transplantation.  The study group was renewed
in 2002, adding several new research centers.  
NIAID, along with several NIH Institutes and
Centers, and JDRF, continues to support the
International Histocompatibility Working Group
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(IHWG).  IHWG, a network of more than 200
laboratories in 44 countries, collects and shares data
on the human leukocyte antigen (HLA) gene
complex.  
Recently, IHWG investigators joined forces with
Hematopoietic Stem Cell Transplant Centers to
develop an international database of transplantation
outcomes and donor-recipient HLA genotypes.
NIAID, with the National Center for Minority
Health and Health Disparities, continues to support
the demonstration and education research projects
aimed at increasing minority involvement in organ
donor registries.  The Louisiana Legacy Donor
Registry is working to increase organ donations by
using new and nontraditional approaches to donor
recruitment, improving the consent process, and
facilitating the medical community’s access to donor
registry information.  NIAID continues to support
the Minority Community Outreach Program on
Organ Donation and Transplantation at the Hope
Heart Institute in Seattle, Washington.  A second
research project at the Hope Heart Institute seeks to
increase organ donation among rural American
Indians and Alaska Natives.
Tuberculosis 
During 2000, approximately 78 percent of active
tuberculosis (TB) cases were reported among racial
and ethnic minorities.  Problems of urban poverty,
high HIV infection rates, and the effects of
household overcrowding may contribute to the
disproportionate impact of TB on minorities.
Over the past decade, NIAID has dramatically
boosted funding for TB research, which has allowed
the Institute to support a number of initiatives and
a markedly expanded community of TB researchers.
NIAID’s extramural TB research program currently
supports more than 231 grants for basic, applied,
and clinical research, including awards to support
the genomic sequencing of Mycobacterium
tuberculosis (M.tb) and other strains of the
bacterium that cause TB.  
NIAID continues to support the Tuberculosis
Research Unit at Case Western Reserve University,
established to conduct clinical trials of potentially
new TB therapeutic, preventive, and diagnostic
strategies.  NIAID’s Blueprint for TB Vaccine
Development, presented at the 1998 International
Symposium for Tuberculosis Vaccine Development
and Evaluation, outlines the specific steps needed to
develop improved TB vaccines.  A task force will
oversee the implementation of the blueprint.
NIAID’s Vaccine Treatment and Evaluation Unit in
St. Louis, Missouri, will work with the Global
Vaccine Foundation to conduct a phase I safety and
immunogenicity trial on a new anti-TB vaccine
(recombinant bacille Calmette-Guerin vaccine),
expected to begin in early spring 2004.  
Through the Tuberculosis Research Materials and
Vaccine Testing contract at Colorado State
University, NIAID provides TB research reagents to
qualified investigators throughout the world.
During 2003, 121 individual vaccines or adjuvant
candidates have been tested, with 15 vaccine testing
experiments completed, 16 experiments in process,
and 7 under development.  The Southern Research
Institute in Birmingham, Alabama, maintains an
NIAID-supported Tuberculosis Antimicrobial
Acquisition and Coordinating Facility (TAACF).
TAACF has contacted more than 3,500 chemists
throughout the world seeking candidate anti-TB
compounds.  More than 60,000 candidate anti-TB
compounds have been received from academic and
private-sector investigators, principally in the United
States and Europe, with growing involvement of
scientists from Africa, Asia, Australia, South
America, and other geographic sites.  
Sexually Transmitted Infections
Sexually transmitted infections (STIs) are critical
global and national health priorities because of their
devastating impact on women and infants and their
causal association with HIV infection.  Reported
rates of some STIs, such as gonorrhea and syphilis,
are as much as 30 times higher for African
Americans than for whites.  This disparity is due to
many factors, including differences in the
distribution of poverty, health-seeking behaviors,
and access to quality health care.  NIAID supports
individual investigator-initiated research grants and
Minorities and Biomedical Research
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a variety of research programs for the development
of more effective prevention and treatment
approaches for STIs.  Research efforts include
developing and licensing vaccines, topical
microbicides, and treatments for microbes that
cause STIs; understanding the long-term health
impact of sexually transmitted pathogens in various
populations; stimulating basic research on the
pathogenesis, immunity, and structural biology of
these pathogens; and developing better and faster
diagnostics.  
NIAID’s ongoing efforts include the STD
Cooperative Research Centers, the STD Clinical
Trials Unit, and the Topical Microbicides Program
Projects.  NIAID recently intensified efforts in
syphilis research, especially in the development of
new, improved biomedical tools to complement and
sustain CDC’s Syphilis Elimination Program.  In
addition, NIAID continues to initiate and support a
variety of other STI research projects, including the
development and evaluation of STI diagnostics
designed for point-of-care use through the Small
Business Innovation Research mechanism, grants for
the development of vaccines to prevent chlamydial
and gonorrheal infections, and a herpes vaccine
efficacy trial.  
Hepatitis C
Hepatitis C virus (HCV) infection is the most
common chronic blood-borne viral infection in the
United States.  Various surveys indicate that HCV
disproportionately affects minority populations.  At
the same time, available HCV treatments are less
effective for African Americans than other
populations.
NIAID has aggressively pursued the expansion of
HCV research through its development of the
“Hepatitis C Framework for Progress.”  With the
aid of participating Institutes and Centers, an NIH-
wide framework was drafted that incorporates
varying individual missions into a cohesive global
plan.  NIAID is investigating clinical manifestations
to develop noninvasive methods to evaluate current
disease state, to predict outcomes, and to prevent or
reverse disease progression.
Currently, NIAID provides funding support to
six hepatitis C Cooperative Research Centers, one
of the cornerstones of NIAID’s HCV research.
Other NIAID HCV research activities include
partial support for the ancillary studies of the
NIDDK-sponsored trial “Hepatitis C Antiviral
Long-term Treatment against Cirrhosis (HALT-C)”;
the development of robust and economical cell
culture and animal models; support for two
antiviral screening tools via its in vitro screening
contract programs; activities to broaden HCV
research and development; the “Liver and Pancreatic
Disease in HIV Infection” program announcement
sponsored jointly with NIDDK to stimulate
research on the pathogenesis and therapeutics of
liver and pancreatic disease associated with the
co-infections (e.g., hepatitis B, hepatitis C) that
occur in patients with HIV infection; and research
investigating the relationships between hepatitis C
virus replication, evolution, and disease progression
in American Indians and Alaska Natives.  
Pneumonia
Pneumococcal pneumonia is an infection in the
lungs caused by the Streptococcus pneumoniae.  Rates
of invasive infection increase with age and are
disproportionately higher among certain minority
populations.  NIAID supports an efficacy and safety
phase III randomized trial in 8,292 Navajo and
White Mountain Apache children using the licensed
7-valent pneumococcal conjugate vaccine, Prevnar.
This study shows that Prevnar is capable of
preventing disease in the general U.S. population.  
Acquired Immunodeficiency Syndrome
Although AIDS affects all racial groups, the disease
continues to disproportionately affect minority
populations.  African Americans and Hispanics
constitute 61 percent of the AIDS cases in the
United States.  Of the new AIDS cases reported in
2002, 55 percent were African American,
13 percent Hispanic, 32 percent white, and less
than 1 percent American Indian, Alaska Native, and
Asian-Pacific Islander.  Among women, African
Americans and Hispanics account for 81 percent of
AIDS cases.  Among men, African Americans and
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Hispanics account for 64 percent of cases.  Minority
children also are disproportionately affected by
AIDS.  
As the HIV/AIDS epidemic continues to expand in
minority communities, enrolling minority patients
in HIV/AIDS clinical trials is particularly urgent.
People of minority backgrounds face unique social,
economic, and medical issues when coping with the
challenges associated with HIV/AIDS infection,
and, therefore, one of the greatest challenges facing
HIV/AIDS researchers today is the recruitment and
retention of minority patients for clinical trials.  An
additional challenge is the recruitment of
underrepresented minority investigators to AIDS
and AIDS-related clinical and basic research
disciplines.  Consequently, NIAID supports a
comprehensive portfolio of biomedical and
behavioral research aimed at preventing and treating
HIV disease in minority communities, training
minority investigators, and fostering infrastructure
development.
NIAID directs a large therapeutic clinical trials
program consisting of three groups: the Adult AIDS
Clinical Trials Group (AACTG), the Pediatric AIDS
Clinical Trials Group (PACTG), and the Terry
Beirn Community Programs for Clinical Research
on AIDS (CPCRA).  AACTG, PACTG, and
CPCRA strive to ensure that a sufficient proportion
of minority individuals is enrolled in clinical trials.  
NIAID’s HIV/AIDS clinical research networks
provide opportunities for community
representatives to participate in the research process
through local, national, and international
Community Advisory Boards.  In addition, NIAID
recently released the “Enrolling Women and
Minorities in HIV/AIDS Research Trials” program
announcement to fund innovative approaches to
access, enroll, and retain women and racial/ethnic
minorities in HIV/AIDS research trials in the
United States.  
NIAID’s epidemiologic research explores the clinical
course and factors contributing to the transmission
of HIV/AIDS infection in a variety of populations.
NIAID supports several studies including the
Women and Infants Transmission Study, which
targets inner-city women and their children; the
Women’s Interagency HIV/AIDS Study, which
explores the clinical course of HIV/AIDS infection
in women with a focus on minority women; and
the Multicenter AIDS Cohort Study, a prospective,
longitudinal study of HIV/AIDS disease in
homosexual and bisexual men.  
NIAID continues to support efforts to develop an
effective HIV vaccine.  Established in 2000, the
HIV Vaccine Trials Network (HVTN) is a
collaboration of domestic and international clinical
sites dedicated to developing a preventive HIV
vaccine.  HVTN tests and evaluates candidate
vaccines in clinical trials.  There are 18 sites in the
United States and 13 sites overseas, including sites
in Africa, Asia, South America, and the Caribbean.
HVTN’s global capacity will allow for rapid
expansion and the ability to perform large-scale
studies of suitable vaccines as more vaccine
candidates enter the pipeline for testing and
development.  Currently, HVTN is conducting six
phase I and two phase II clinical trials of candidate
HIV vaccines.  In addition to conducting clinical
studies, HVTN develops community outreach
programs to educate people about HIV/AIDS and
vaccine research.  
NIAID is currently in the second year of its HIV
Vaccine Communications Campaign.  Targeting 
at-risk populations, the HIV Vaccine
Communications Campaign is developing and
implementing a national education campaign to
increase awareness and support for HIV vaccine
research, especially in at-risk populations.  This past
year, a national survey was completed that evaluated
the attitudes toward and knowledge of HIV vaccine
research in the general population, as well as in
segmented groups of African Americans, Hispanics,
and men who have sex with men.  The
Communications Campaign is working to correct
the misperceptions that exist regarding HIV vaccine
trials and, at the same time, provide general
information about HIV vaccine research to
minority communities.  
Minorities and Biomedical Research
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NIAID established the HIV Prevention Trials
Network (HPTN) in 2000 in an effort to reduce
the worldwide spread of HIV.  HPTN is a global
network of clinical trial sites with 9 sites in the
United States and 16 international sites in Africa,
Asia, Europe, and South America.  The network
explores a variety of nonvaccine prevention
strategies to reduce HIV/AIDS transmission, such
as testing and developing biomedical and behavioral
intervention programs.  Additional prevention
efforts include research to prevent mother-to-child
transmission of HIV; evaluation of simpler and less
costly prevention regimens suitable for global use;
support for the Centers for AIDS Research, which
address problems in the enrollment and retention of
women and minority groups in AIDS clinical trials;
and promotion of the development of minority
scientists in AIDS research.
NIAID Outreach Activities
Disseminating research results to the media, health
professionals, and the public is an important aspect
of NIAID’s mission.  Outreach activities include
producing and publicizing print, audiovisual, and
Web-based materials; distributing materials at
professional and community meetings; and
sponsoring workshops and conferences for
community health care providers and the public.
Materials such as press releases, information sheets,
and booklets are distributed worldwide in response
to more than 10,000 requests from people who
contact NIAID each year.  The NIAID Web site is
visited 1.5 million times each month.  Hundreds of
thousands of inquirers request materials or
download information from the NIAID Web site
each year.  Periodic e-mails provide NIAID research
news and information on advances that specifically
relate to an organization’s research interests.  
Minority Researchers’ Training and
Enhancement Programs
Through innovative programs and outreach efforts,
NIH continually works to increase the number of
minority researchers in the field of biomedical
research.  In addition to supporting NIH-wide
programs, NIAID supports a variety of minority
programs for biomedical research, from high school
through postdoctoral training.  NIAID’s Office of
Special Populations and Research Training
(OSPRT) is engaged in an extensive outreach
campaign targeting colleges, universities, medical
centers, and professional organizations to encourage
the participation of minority investigators in
NIAID research activities.  OSPRT programs
include the Introduction to Biomedical Research
Program (IBRP) and the Bridging the Career Gap
for Underrepresented Minority Scientists workshop.
In addition, OSPRT plays a key role in reporting
data about women and minority inclusion in phase
III clinical trials and serves as NIAID’s coordinator
and liaison for the Institute’s Strategic Plan for
Addressing Health Disparities.
IBRP seeks to encourage academically talented
members of minority groups to pursue careers in
life sciences and biomedical research through its
extramural and intramural research arms.  The
Richard M. Asofsky Scholars In Research (ASIR) is
the IBRP extramural arm and is administered
through OSPRT.  The intramural arm of IBRP is
known as the Introduction to NIAID Research
Opportunities (INRO) and is administered through
the Division of Intramural Research’s Office of
Special Emphasis.
The ASIR program provides opportunities for
underrepresented minority students to work with
extramural principal investigators in a mentorship
relationship.
In FY 2003, INRO provided qualified minority
students with a 3-day program that introduced
them to research opportunities at NIAID and
included scientific lectures and tours of some of the
NIAID laboratories. 
NIAID also collaborates with minority
organizations to disseminate information about
biomedical research careers to members of
underrepresented groups.  The Research Centers in
Minority Institutions (RCMI) program provides
grant support to predominantly minority health
professional schools and graduate institutions that
offer a doctorate in the health professions or health-
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related sciences for the purpose of strengthening
and augmenting their human and physical resources
for conducting biomedical or behavioral research.
Currently, 17 institutions participate in the RCMI
program.
The Interamerican College of Physicians and
Scientists (ICPS) is one outreach activity supported
by OSPRT that targets a specific underrepresented
community.  Founded in 1979, ICPS promotes
cooperation among U.S. Hispanic physicians and
seeks to advance their professional and educational
development.  ICPS is the only national
organization representing Hispanic physicians.  
Targeting individuals who receive NIAID minority
training and research supplemental awards, the
Bridging the Career Gap program seeks to provide
young, minority investigators with the tools and
information needed for a successful career in
biomedical research.  The initiative consists of a
2-day seminar addressing career choices,
networking, the importance of selecting the right
mentor, and the NIH grant system and
components.  
NIAID continues to work with schools on several
programs that foster an interest in science and
research careers among younger students.  The
Institute supports the Partners in Education
Program that provides students in the Washington,
DC, area with a scientific environment in which
they can nurture their interest in the sciences.  In
FY 2001, NIAID co-funded the Temple University
Minority Access to Biomedical Research Careers
partnership program.  The goal of the program is to
provide additional math and science instruction to
outstanding minority middle school students and
encourage them to pursue graduate degrees in
biomedical research.  NIAID’s Rocky Mountain
Laboratories teamed with local middle and high
schools in Montana to present a program that
introduces students to biomedical research.  
NIAID continues to strengthen its research on
infectious and immunologic diseases that contribute
to health disparities experienced by minority
populations, as well as programs designed to build a
new cadre of minority researchers.  These efforts,
coupled with the Institute’s increased outreach to
minority groups, will help ensure that NIAID
research benefits all individuals in the United States.
Minorities and Biomedical Research
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Allergy, Immunology and Transplantation
NIAID’s Strategic Plan for Addressing Health
Disparities outlines two main objectives with respect
to minority health in the areas of allergy,
immunology, and transplantation:
• Support basic and clinical research on immune-
mediated diseases, including asthma and allergic
diseases, autoimmune diseases, and rejection of
transplanted organs, tissues, and cells, that will
lead to a better understanding of these diseases and
improved prevention and treatment strategies.
• Increase the number of minority biomedical
scientists through individual and institutional
support for undergraduate, graduate, and
postgraduate research training in a variety of
disciplines related to immune-mediated diseases.
Asthma and Allergic Diseases
Asthma and allergic diseases are among the major
causes of illness and disability in the United States.
Approximately 50 percent of Americans have
positive skin tests to at least 1 of 10 allergens that
contribute to allergic illness (NHANES III, the
1987–1994 National Health and Nutrition
Examination Survey.  J Allergy Clin Immunol
2002;110:381-7).  Chronic allergic conditions can
significantly decrease personal quality of life, patient
well-being, employee productivity, and school
performance and attendance.  Compared with white
children of the same age, African American children
have a higher prevalence of allergy to cockroaches,
house dust mites, and molds (Alternaria).  Similarly,
Mexican American children have a higher prevalence
of allergy to cockroaches and house dust mites
(NHANES III.  J Allergy Clin Immunol
2001;108:747-52).  
Asthma affects more than 17 million Americans,
resulting in more than 500,000 hospitalizations and
5,000 deaths annually.  African Americans are
disproportionately affected by asthma.  In 2001, the
current asthma prevalence among non-Hispanic
African Americans was approximately 10 percent
higher than among non-Hispanic whites and
approximately 40 percent higher than among
Hispanics.  Non-Hispanic African Americans had an
asthma attack prevalence about 20 percent higher
than among non-Hispanic whites and almost
60 percent higher than among Hispanics (Centers
for Disease Control and Prevention [CDC], “Asthma
Prevalence, Health Care Use and Mortality, 
2000-2001,” National Center for Health Statistics,
January 28, 2003.  www.cdc.gov/nchs/products/
pubs/pubd/hestats/asthma/asthma.htm).  The
disparity in asthma prevalence was also greater
among African American children: asthma was more
prevalent among African American children younger
than 18 years (7.4 percent) than among white
children (5.0 percent) of the same age (Pediatrics
2002;110:317).  In 1998, asthma accounted for an
estimated $12.7 billion in expenditures, with
$7.4 billion in direct medical expenditures and
$5.3 billion in indirect costs (J Allergy Clin Immunol
2001;107:3-8).  
Asthma is a long-term, generally progressive lung
disease characterized by episodes of obstructed
airways.  The cellular infiltrates and inflammatory
mediators of asthma are thought to be similar to
those of other allergic diseases, but asthma mediators
also appear to cause airway hyperreactivity.  Chronic
inflammation of the airways is recognized widely as a
key factor in the development of asthma, and, as a
result, anti-inflammatory medications have become a
mainstay of asthma therapy.  Many immune-based
therapies are in the early stages of development or
are being studied as investigational agents.  However,
much needs to be learned before the more promising
immune-based approaches can be developed into
licensed therapies.  
Although allergic reactions are an important cause of
asthma, nonimmunologic factors (e.g., viral
infections, exposure to environmental tobacco smoke
and pollutants) also contribute to the
pathophysiology of this disease.  Recent studies
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suggest that the development of asthma begins
around the first months of gestation.  These and
other promising findings offer new opportunities to
initiate basic and clinical research aimed at clearly
defining the early-life perturbations of the immune
system that lead to the development of asthma.  
For more than a decade, improving the
management of asthma in children has remained a
high priority for NIAID.  Preliminary results from
the Inner-City Asthma Study (1996-2001), 
co-sponsored by the National Institute of
Environmental Health Sciences, indicate that
physician education and an extensive environmental
intervention can successfully reduce asthma
symptoms among inner-city children and can
continue to reduce symptoms 1 year after
intervention.  The environmental intervention
involved home-based education to reduce exposure
to environmental triggers, including environmental
tobacco smoke, cockroaches, house dust mites,
mold, furry pets, and rodents.  Data show that the
environmental intervention resulted in 2 to 4 weeks
of additional symptom-free days, a reduction in
unscheduled medical visits, and improvements in
asthma symptoms.  The physician feedback
intervention provided physicians with up-to-date
information on patients’ asthma symptoms,
medication, and health care utilization.  Data show
that the physician feedback intervention resulted in
a 20 percent decrease in unscheduled visits for
poorly controlled asthma.  The final results of the
Inner-City Asthma Study should reveal significantly
improved health for inner-city children with
asthma, as well as an overall reduction of the high
medical, economic, and social costs associated with
this disease.  The Inner-City Asthma Consortium
(ICAC), established by NIAID in 2002, will
evaluate the safety and efficacy of promising
immune-based asthma treatments developed to
reduce asthma severity and prevent disease onset in
inner-city children.  ICAC will conduct research to
determine the mechanisms of action of immune-
based therapies; develop and validate biomarkers to
measure disease stage, progression, and therapeutic
effect; and conduct research to understand the
immunopathogenesis of asthma in inner-city
children.  
NIAID’s Asthma and Allergic Diseases Research
Centers program is the cornerstone of the
pathobiology component of NIAID asthma and
allergy research.  This national network of centers
conducts basic and clinical research on the
mechanisms, diagnosis, treatment, and prevention
of asthma and allergic diseases.  In 2003, NIAID
funded 4 new Asthma and Allergic Diseases
Research Centers, bringing the total number of
centers to 13.  
In 2003, NIAID requested applications for research
projects aimed at understanding the early life
changes in immune function that lead to the
development of asthma (RFA-AI-03-041 “Immune
System Development and the Genesis of Asthma”).
Identifying the cellular and molecular processes
involved in the onset of asthma provides the basis
for devising novel and effective immune-based
strategies for the treatment and prevention of this
disease.  This approach will allow researchers to
develop strategies that do not compromise immune
system integrity and are not hampered by the
limitations inherent in current therapies.  The
Immune System Development and the Genesis of
Asthma program will be launched in 2004 and will
be co-funded by the National Heart, Lung, and
Blood Institute (NHLBI).
In response to provisions in the Children’s Health
Act of 2000 (P.L. 106-310), NIAID participates in
the Federal Liaison Group for Asthma, a
subcommittee of the National Asthma Education
and Prevention Program.  
Autoimmune Diseases
Autoimmune diseases are caused by the
misdirection of an immune response toward the
body’s own tissues, causing the immune system
mistakenly to attack the body’s own cells, tissues,
and organs.  People suffering from autoimmune
diseases often endure loss of function, disability,
hospitalizations, outpatient visits, decreased
productivity, and impaired quality of life.
Autoimmune diseases include systemic lupus
erythematosus (SLE), type 1 diabetes, scleroderma,
multiple sclerosis, Crohn’s disease, Graves disease,
and rheumatoid arthritis.  Collectively, autoimmune
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diseases afflict more than 5 percent of the U.S.
population, and women are more likely to suffer
from an autoimmune disease than men.  Several
autoimmune diseases, such as systemic lupus
erythematosus and scleroderma, disproportionately
affect minority populations.  
SLE, or “lupus,” is a chronic, inflammatory,
multisystem disorder of the immune system in
which the body produces antibodies that target the
body’s healthy cells and tissues.  SLE occurs in 1 of
2,000 Americans with varying severity.  SLE is more
common and more severe in African American
women, occurring in as many as 1 in 250 young
African American women.  SLE is twice as prevalent
among African American men as among white men.
Reports also indicate an increased prevalence of SLE
and rheumatoid arthritis among many American
Indian and Alaska Native tribes.
Scleroderma is an autoimmune disease involving the
abnormal growth of connective tissues supporting
the skin and internal organs.  There are two main
classes of scleroderma: localized and systemic.
Localized scleroderma affects the skin and
musculoskeletal system.  Systemic scleroderma
affects the skin and musculoskeletal system and can
also affect blood vessels and damage the heart,
lungs, and kidneys.  The number of Americans
affected by systemic scleroderma is estimated to
range from 40,000 to 165,000.  Systemic
scleroderma affects more African American women
than women of European descent.  
NIAID supports a broad portfolio of basic,
preclinical, and clinical research aimed at
understanding the pathogenesis of autoimmune
diseases.  Researchers investigate new ways to
modify the immune system and will apply this
knowledge to the identification and evaluation of
promising approaches to treat and prevent
autoimmune diseases.  Research programs include
Autoimmunity Centers of Excellence (ACEs);
Autoimmune Disease Prevention Centers; and
multidisciplinary research targeting the
identification, characterization, and definition of
gender-based differences in the immune response.
The ACEs support collaborative basic and clinical
research on autoimmune diseases, including pilot
clinical trials of immunomodulatory therapies.  In
2003, the ACEs were renewed and expanded to
include nine separate institutions.  The centers
bring together subspecialists (e.g., neurologists,
gastroenterologists, rheumatologists) and basic
scientists to increase clinical and research
collaborations on autoimmunity.  These centers
conduct clinical trials to evaluate therapeutic
interventions for several autoimmune diseases,
including SLE.  Trials for new immunomodulatory
interventions and studies of mechanisms of action
are being developed.  The ACEs are co-sponsored
by the National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) and the NIH Office
of Research on Women’s Health (ORWH).
The Autoimmune Disease Prevention Centers
conduct basic research on the development of new
targets and approaches to prevent autoimmune
diseases.  In fiscal year (FY) 2003, Autoimmune
Disease Prevention Centers supported 14 pilot
projects to test innovative approaches that may lead
to the development of novel targets for disease
prevention or assays for biomarkers of disease
progression.  The centers continue to evaluate
supported projects through pilot and clinical
studies.  The prevention centers are co-sponsored by
NIDDK, the National Institute of Child Health
and Human Development (NICHD), ORWH, and
the Juvenile Diabetes Research Foundation
International (JDRF).  
NIAID established the “Sex-Based Differences in
the Immune Response” (RFA-AI-01-005) research
initiative in 2001 to better understand differences in
immune response between males and females.
Research supported under this initiative will
identify, characterize, and define sex- and gender-
based differences in immune responses.  Studies
include basic and clinical investigations of sex
differences regulated by hormonal and
nonhormonal mechanisms in response to exogenous
antigens, the innate and adaptive immune response,
and systemic and mucosal immunity.  This initiative
is co-sponsored by the National Institute of
Neurological Disorders and Stroke, the National
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Institute of Arthritis and Musculoskeletal and Skin
Diseases, ORWH, and the National Multiple
Sclerosis Society.  
NIAID continues to support the Immune Tolerance
Network (ITN).  Co-sponsored by NIDDK and
JDRF, ITN is an international consortium of more
than 80 investigators throughout the United States,
Canada, and Europe.  Investigators are dedicated to
the clinical evaluation of novel, tolerance-inducing
therapies for autoimmune diseases, asthma and
allergic diseases; and the development of tolerance-
inducing therapies to prevent the rejection of
transplanted organs, tissues, and cells.  The goal of
tolerance-inducing therapies is to “re-educate” the
immune system to eliminate injurious immune
responses and graft rejection, while preserving
protective immunity against infectious agents.  ITN
conducts integrated studies on the underlying
mechanisms of approaches and develops and
evaluates markers and assays to measure the
induction, maintenance, and loss of tolerance in
humans.  More information about ITN is available
at www.immunetolerance.org.
The NIAID Clinical Trials Network for Stem Cell
Transplantation for Autoimmune Diseases will
evaluate the safety and efficacy of hematopoietic
stem cell transplantation for treating severe
autoimmune diseases, including SLE and
scleroderma.  
NIAID supports the Multiple Autoimmune Disease
Genetics Consortium (MADGC), a repository of
genetic and clinical data and materials from families
in which two or more individuals are affected by
two or more distinct autoimmune diseases.
MADGC provides materials to advance research
aimed at discovering the human immune response
genes involved in autoimmunity.  MADGC has
enrolled more than 150 families since May 2000.
More information can be found at www.madgc.org.
NIAID chairs the NIH Autoimmune Diseases
Coordinating Committee (ADCC), established in
FY 1998 at the request of Congress to increase
collaboration and facilitate coordination of research
among NIH Institutes and Centers, other Federal
agencies, and private groups interested in these
diseases.  The ADCC Autoimmune Diseases
Research Plan was presented to Congress in 2002.
The research plan can be found at www.niaid.nih.
gov/dait/pdf/ADCC_Report.pdf.  
Transplantation
The principal goal of transplantation is the physical
and functional replacement of failing organs and
tissues.  The most striking advances in
transplantation have come in the past 30 years, with
improvements in surgical techniques and the
development of immunosuppressive agents to
inhibit a recipient’s immune responses against
grafts.  These advances have made transplantation
the preferred treatment for many end-stage organ
diseases.  Today, transplantation procedures are
performed using more than 25 different organs and
tissues with first-year graft survival rates often
exceeding 80 percent.  Despite these successes, two
major impediments remain:  immune-mediated
graft rejection and the critical shortage of donor
organs.  The primary reason for graft failure is a
recipient’s vigorous immune response to the graft.
Improvements in immunosuppressive therapy have
dramatically increased graft survival for all organs
during the first year after transplantation.  However,
long-term graft survival has not improved
significantly in the past two decades because of
chronic graft failure.  The mechanisms of chronic
graft failure differ from those of acute rejection and
are less well understood.  
Organ transplantation represents a health disparity
for African Americans.  It has been shown that
African Americans are less likely to be identified as
candidates for renal transplantation, often lack
suitable donors, and tend to remain longer on
transplant waiting lists than other groups.
Although African Americans comprise
approximately 35 percent of patients on the renal
transplant waiting list, the organ donation rate
among African Americans is lower than that of
other racial groups.  
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Immune-Mediated Graft Rejection 
Although advances in surgical procedures and
immunosuppressive therapies have greatly increased,
1-year graft survival rates for all organs and tissues
and long-term graft survival is relatively unchanged.
NIAID supports a broad portfolio of research to
address immune-mediated graft rejection, including
basic research in transplantation immunology,
preclinical evaluation of new therapies, and clinical
trials of promising therapeutic approaches to
improve short- and long-term graft survival.  The
major goals of transplantation research are to
understand the pathways whereby the immune
system recognizes transplanted organs, tissues, and
cells; characterize the cellular and molecular
components of acute rejection and chronic graft
failure; evaluate novel therapies for treating rejection
and prolonging graft survival in preclinical models;
develop and implement strategies for immune
tolerance induction; and conduct clinical trials of
new therapies to improve graft survival while
minimizing the toxic side effects of
immunosuppressive drugs.  
Kidney transplantation accounts for 59 percent of
all solid-organ transplant procedures and is the
preferred therapy for end-stage renal disease (Organ
Procurement and Transplantation Network.
www.optn.org).  In 2003, NIAID renewed the
Cooperative Clinical Trials in Pediatric
Transplantation (CCTPT) program.  The program
supports multicenter clinical trials of novel
approaches to prevent acute and chronic graft
rejection in pediatric kidney transplantation,
evaluates modifications of immunosuppressive drug
regimens to mitigate unwanted side effects of
immunosuppression, and assesses pretransplant
immunotherapy to improve transplantation
outcomes.  Clinical trials that continue to accrue
subjects include a study comparing the
immunosuppressive drug sirolimus to the standard
treatment for chronic graft failure, a study of the
effects of steroid withdrawal in pediatric transplant
recipients, an evaluation of intravenous
immunoglobulin as an agent to reduce existing
immunity to potential donor organs, and the study
of transplantation for high-risk kidney transplant
candidates.  CCTPT conducts mechanistic studies
to determine the effect of these interventional
approaches on the immune system.  The
mechanistic studies have led to novel approaches for
noninvasive diagnosis of acute rejection as well as
innovative approaches for detecting T cells that may
regulate the immune response to grafts.  
Patients infected with HIV/AIDS are at significant
risk for end-stage organ disease.  Before the advent
of highly active antiretroviral therapy (HAART),
HIV-positive (HIV+) patients often were not
considered for transplants on the basis of poor
prognosis.  HAART has significantly increased the
number of HIV+ patients with end-stage kidney or
liver disease as potential candidates for
transplantation.  NIAID’s Division of Allergy,
Immunology and Transplantation and NIAID’s
Division of AIDS launched a study on the
outcomes of kidney or liver transplantation for
HIV+ patients in 2003.  The primary aim of this
prospective, multicenter cohort study is to evaluate
the safety and efficacy of solid organ transplantation
in HIV+ patients who undergo kidney or liver
transplantation.  
Despite substantial improvements in short-term
graft survival, long-term graft survival remains poor,
primarily because of chronic graft failure.  In 2001,
NIAID and NHLBI renewed the
Immunopathogenesis of Chronic Graft Rejection
Program, designed to enhance knowledge of chronic
graft failure.  Little is known about the etiology of
chronic graft failure, including the factors that
determine onset and severity, the targets of immune
reactivity, and the factors that control the degree of
variability in the rejection process between patients.
The Immunopathogenesis of Chronic Graft
Rejection Program will enhance understanding of
both the immunologic and nonimmunologic
mechanisms that underlie chronic graft failure
rejection of solid organs, improve diagnostic criteria
to predict graft failure, and identify novel
approaches for clinical intervention.
Improvements in immunosuppressive therapy have
dramatically reduced acute graft rejection and have
increased the 1-year graft survival rate for all organ
transplants.  However, many serious side effects
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such as infections and malignancies are associated
with the use of systemic immunosuppressive drugs
to prevent graft rejection.  Reducing the risk of
serious side effects while improving graft and
patient survival is a priority in transplantation
immunology.  One promising alternative to
immunosuppression is to interrupt or modify the
immune response to establish specific tolerance to
the graft.  NIAID, in collaboration with NIDDK,
supports the Non-Human Primate Immune
Tolerance Cooperative Study Group.  The goal of
this program is to evaluate the safety and efficacy of
novel tolerogenic regimens in animal models of
kidney and islet transplantation.  The study group
has demonstrated long-term graft acceptance using
tolerogenic regimens in both kidney and islet
allograft recipients.  The study group was renewed
in 2002, adding several new research centers.  The
new research centers will allow a larger number of
tolerance-induction strategies to be rigorously
evaluated.  NIAID supports breeding colonies of
rhesus and cynomolgus macaques to accelerate the
research conducted through this program.  
Histocompatibility and Immunogenetics
NIAID, along with several NIH Institutes and
Centers, and JDRF, continues to support the
International Histocompatibility Working Group
(IHWG).  IHWG, a network of more than 200
laboratories in 44 countries, collects and shares data
on the human leukocyte antigen (HLA) gene
complex.  Researchers seek to (1) advance
histocompatibility testing by discovering new HLA
alleles and developing new tissue-typing reagents
and methods, (2) elucidate HLA associations with
autoimmune diseases, and (3) improve the
outcomes of hematopoietic stem cell (HSC)
transplantation through better donor-recipient
matching.  Recently, IHWG investigators joined
forces with HSC transplant centers to develop an
international database of transplantation outcomes
and donor-recipient HLA genotypes.  The
international database will help determine optimal
matching criteria for HSC transplants between
unrelated individuals and increase transplantation
access for ethnically diverse populations.  In
addition, IHWG researchers are working to identify
single nucleotide polymorphisms (SNPs) in
immune-response genes.  SNPs may account for the
increased susceptibility of certain individuals or
groups to immune-mediated diseases.  SNP data
have been gathered for more than 100 immune-
response-related genes.  More information about the
IHWG can be found at www.ihwg.org.
Donor Organ Shortage
In 2001, a total of 24,897 organ transplants were
performed in the United States, including 14,774
kidneys, 5,328 livers, 2,154 hearts, 554 pancreata,
1,042 lungs, 107 intestines, 33 heart-lung
combinations, and 905 kidney-pancreas
combinations.  For the second consecutive year,
living donors exceeded deceased donors (6,617
versus 6,183) (Organ Procurement and
Transplantation Network, September 5, 2003.
www.optn.org).  However, the limited availability of
donor organs is the main factor that restricts the
number of transplantation procedures performed
each year in the United States.  The waiting list for
transplants has quadrupled in size since 1988 to
more than 80,000 patients, and, as a result, 6,482
patients died in 2002 while awaiting transplants.
NIAID supports efforts to increase organ donation
by improving donor registries and developing and
testing educational interventions.  Efforts to
increase organ donation emphasize the involvement
of African Americans and other underrepresented
minority populations that are at greater risk of 
end-stage renal disease.  
NIAID, with the National Center for Minority
Health and Health Disparities, continues to support
demonstration and education research projects
aimed at increasing minority involvement in organ
donor registries.  The Legacy Donor Registry in
Louisiana is working to increase organ donation by
using new and nontraditional approaches to organ
donor recruitment, improving the consent process
to enhance organ donations, and facilitating the
medical community’s access to donor registry
information.  The program’s Corporate Donor
Program began in 2000 and has conducted organ
A Partnership for Health
6
donation awareness events that reach major
Louisiana corporations and employers.  More
information about the Legacy Donor Registry can
be found at www.lopa.org/about_leg_rg.php.
NIAID continues to support the Minority
Community Outreach Program on Organ
Donation and Transplantation at the Hope Heart
Institute in Seattle, Washington.  This unique
community-based outreach network is dedicated to
increasing organ donation among minority
populations in Seattle and Tacoma, Washington.
Projects supported by the program involve (1) the
development and distribution of educational
materials in African American and Asian
communities, (2) public service announcements at
Department of Motor Vehicles offices, and (3) the
development of a computerized database of
community residents to record donation
preferences, educational levels, and medical
histories.  A second research project developed by
the Hope Heart Institute includes an educational
video, “New Traditions of Sharing: Alaska Native
Stories of Organ Donation and Transplantation”
and other culturally sensitive educational materials
that seek to increase organ donation among rural
Alaska Natives.
Microbiology and Infectious Diseases
The microbiology and infectious diseases segment
of NIAID’s scientific agenda includes intramural
and extramural research to control and prevent
diseases in humans caused by virtually every
infectious agent except HIV.  NIAID supports a
wide spectrum of projects ranging from basic
biomedical research (e.g., studies of microbial
physiology and antigenic structure) to applied
research (e.g., developing diagnostic tests and
clinical trials to evaluate potential drugs and
vaccines).
Tuberculosis 
A century ago, tuberculosis (TB) was a leading
cause of death in the United States.  Through the
efforts of physicians, researchers, public health
officials, improvements in living conditions, and the
introduction of effective drug therapies, the number
of TB cases and deaths in the United States declined
steadily from the early 20th century until 1985.  
Because of the HIV epidemic, new cases of TB in
the United States increased unexpectedly between
1985 and 1992.  Starting in 1992, however, a large
influx of Federal funds and a renewed emphasis on
TB therapy, prevention, and control have led to
declining TB cases and death rates in the United
States.  During 2002, a total of 15,078 TB cases
were reported to the CDC.  This number represents
a 5.7-percent decline in the number of reported TB
cases from 2001, a 43.5-percent decline in reported
TB cases from the 1992 peak of the TB resurgence,
and the lowest recorded TB rate in the United
States since reporting began in 1953 (CDC.
MMWR March 21, 2003).
The continued downward trend in reported TB
cases is thought to reflect at least six factors:
• Improved laboratory methods for prompt
identification of Mycobacterium tuberculosis (M.tb)
• Broader use of drug susceptibility testing
• Expanded use of preventive therapy in high-risk
groups
• Implementation of measures to limit transmission
of M.tb in congregate settings (e.g., hospitals,
homeless shelters, and HIV/AIDS treatment
facilities)
• Improved follow-up of diagnosed cases
• Increased Federal resources
Despite progress in TB reduction over the past 10
years, TB remains a matter of grave concern.
Overall, national declines in TB incidence mask
substantial disparities between rates in the majority
of U.S. residents and rates in two specific
populations.  Foreign-born minorities and 
U.S.-born non-Hispanic African Americans now
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account for approximately three-fourths of the TB
cases in the United States (CDC.  MMWR
March 21, 2003).  A combination of factors is
responsible for the disproportionate impact of TB
on minorities.  Foreign-born minorities emigrating
from TB-endemic countries may harbor TB
infection or already have active TB disease when
they move to the United States.  In addition, urban
poverty, high HIV infection rates, and the effects of
household overcrowding may contribute to the
disproportionately high number of TB cases in
minority populations.  
The link between HIV/AIDS and TB is thought to
be a significant factor in the spread of TB.
Worldwide, TB is the leading cause of death in
individuals with HIV/AIDS infection because TB
accelerates the progression of AIDS by increasing
the replication rate of HIV (Goletti D et al.
J Immunol 157:1271-8, 1996).  At the same time,
persons co-infected with HIV and TB show rapid
progression from infection to active TB disease,
indicating that HIV infection accelerates the
pathogenicity of TB (World Health Organization
[WHO], Tuberculosis Strategy and Operations
[TB-HIV], Jan 2001).  For M.tb-infected persons
not infected with HIV, 1 in 10 individuals may
develop TB over his or her lifetime; in HIV
co-infected individuals with weakened immune
systems, 1 in 10 persons may develop TB during
the next year.  Furthermore, infection with M.tb
accelerates the progression of AIDS, increasing the
replication rate of HIV in M.tb co-infected
individuals (Goletti D et al.  J Immunol 157:
1271-8, 1996).
The TB crisis is intensified by the emergence of TB
caused by multidrug-resistant M.tb.  The long
duration and associated side effects of standard TB
drug treatment often result in patients not
completing their full course of therapy.  When
individuals do not complete their full course of
therapy, single- and multidrug-resistant strains of
TB may emerge that are more difficult and more
expensive to treat.  Patients with drug-resistant
strains may require up to 2 years of treatment and
may remain infectious for longer periods of time
compared with patients with non-multidrug-
resistant organisms (CDC.  Fact Sheet: Treatment of
Drug-Resistant Tuberculosis, June 20, 2000.  www.
cdc.gov/nchstp/tb/pubs/tbfactsheets/250112.htm).
Drug-resistant TB represents a small percentage of
the total cases of TB in the United States, with the
most common form being M.tb strains resistant to
the commonly prescribed TB drug isoniazid.  For
the more than 85 percent of culture-positive cases
in which data on drug resistance were available,
resistance to at least isoniazid was between 7 percent
and 8 percent in 2002.  Among the tested M.tb
strains, resistance to two of the most commonly
prescribed drugs (isoniazid and rifampin) has
increased from 116 cases (1.0 percent) in 2001 to
121 cases (1.2 percent) in 2002 in patients who
have no prior history of drug-resistant TB (CDC.
Surveillance Slides, 2002.  www.cdc.gov/nchstp/
tb/pubs/slidesets/surv/default.htm).
Over the past decade, NIAID has dramatically
boosted funding for TB research.  This increased
funding has allowed the Institute to support a
number of initiatives and a markedly expanded
community of TB researchers.  Higher levels of
funding enabled NIAID to establish the
Tuberculosis Research Unit (TBRU) at Case
Western Reserve University in 1994
(www.tbresearchunit.org).  TBRU conducts clinical
trials of potentially new TB therapeutic, preventive,
and diagnostic strategies.  At the same time, TBRU
continues to make progress in developing surrogate
markers of disease and human protective immunity.
A newly established repository will distribute 
well-characterized clinical samples to TBRU
investigators and their collaborators.  TBRU
activities are coordinated with major organizations
involved in TB research, including CDC, the Food
and Drug Administration, the United States Agency
for International Development, WHO, Global
Alliance for TB Drug Development, and the
International Union Against Tuberculosis and Lung
Disease, and with interested industrial partners.  
NIAID’s extramural TB research program currently
supports more than 230 grants for basic, applied,
and clinical research.  Among the projects
supported by NIAID is an award to The Institute
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for Genomic Research (TIGR) in Rockville,
Maryland, to sequence and annotate Mycobacterium
smegmatis (strain MC2 155), an important model
system used in TB research.  M. smegmatis
microarrays also will be produced as part of this
grant and are expected to be distributed through the
Pathogen Functional Genomics Resource Center in
FY 2004.  For additional information on genome
data, see www.tigr.org/tdb/mdb/
mdbinprogress.html.  
One of NIAID’s high priorities is the development
of improved TB vaccines, which are crucial to the
long-term control of TB worldwide.  NIAID’s
Blueprint for TB Vaccine Development, presented at
the 1998 International Symposium for Tuberculosis
Vaccine Development and Evaluation, outlines the
specific steps needed to develop improved TB
vaccines (www.niaid.nih.gov/publications/
blueprint).  A task force with representatives from
NIAID and several Department of Health and
Human Services (DHHS) agencies, will oversee the
implementation of the report.  NIAID’s Vaccine
Treatment and Evaluation Unit in St.  Louis,
Missouri, will work with the Global Vaccine
Foundation to conduct a phase I safety and
immunogenicity trial on a new anti-TB vaccine
(recombinant bacille Calmette-Guerin vaccine).
This candidate vaccine was originally developed
with NIAID grant support.  Enrollment in the
phase I safety and immunogenicity trial is expected
to begin in early spring 2004.
Through the Tuberculosis Research Materials and
Vaccine Testing contract at Colorado State
University, NIAID provides TB research reagents to
qualified investigators throughout the world.  The
TB research reagents provided by NIAID enable
researchers to work with consistent, high-quality
reagents prepared from the highly contagious and
technically demanding causative M.tb pathogen.
This contract also screens potential TB vaccine
candidates in appropriate animal models.  During
2003, 121 individual vaccines or adjuvant
candidates have been tested, with 15 vaccine-testing
experiments completed, 16 experiments in process,
and 7 under development.  
The Southern Research Institute in Birmingham,
Alabama, maintains an NIAID-supported
Tuberculosis Antimicrobial Acquisition and
Coordinating Facility (TAACF).  TAACF acquires
compounds for screening against virulent M.tb,
maintains a computerized chemical database of
compound structures, coordinates and distributes
compounds for evaluation in vitro and in animal
models, and reports data to suppliers.  TAACF has
contacted more than 3,500 chemists throughout the
world seeking candidate anti-TB compounds.
More than 60,000 candidate anti-TB compounds
have been received from academic and private sector
investigators principally in the United States and
Europe, with growing involvement of scientists
from Africa, Asia, Australia, South America, and
other geographic sites.  For more information,
please visit www.taacf.org.  
NIAID’s Division of Intramural Research has a
substantial intramural program that integrates
genomics and combinatorial chemistry to speed the
development of new antibiotics for the control of
tuberculosis.  At present, intramural scientists are
working on a number of approaches to improve
current anti-TB chemotherapeutics.
Sexually Transmitted Infections
Because of their devastating impact on women and
infants and their causal association with HIV/AIDS,
sexually transmitted infections (STIs) are critical
global and national health priorities.  STIs often
have severe sequelae such as infertility, tubal
pregnancy, cervical cancer, fetal wastage, low
birthweight, congenital or perinatal infection, and
HIV/AIDS infection.  Recent studies indicate that
nonulcerative STIs (e.g., chlamydia, gonorrhea, and
trichomoniasis) and ulcerative STIs (e.g., genital
herpes, syphilis, and chancroid) increase the risk of
HIV/AIDS transmission by at least twofold to
fivefold.  Because HIV/AIDS infection is
characterized by a weakened or nonfunctioning
immune system, it can alter the natural history of
some STIs (e.g., pelvic inflammatory disease and
human papillomavirus infection).
Individuals with STIs are at least 2 to 5 times more
likely than uninfected individuals to acquire HIV if
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they are exposed to the virus through sexual
contact.  In addition, if an HIV-infected individual
also is infected with another STI, that person is
more likely to transmit HIV through sexual contact
than other HIV-infected persons (CDC.  The Role
of STD Detection and Treatment in HIV Prevention.
www.cdc.gov/nchstp/dstd/fact_sheets/facts_std_
testing_and_treatment.htm).
Even though rates of some STIs (e.g., syphilis) saw
an overall U.S.-wide decline in 2001, a recent
report by CDC indicates that STI rates tend to be
higher among African Americans than among
whites.  In 2001, the rate of primary and secondary
syphilis reported in African Americans (11.0 cases
per 100,000 population) was 16 times greater than
the rate reported in whites (0.7 cases per 100,000).
This differential was substantially less than that in
1997, when the rate of primary and secondary
syphilis among African Americans was 44 times
greater than the rate reported among whites.
Although STI rates tend to be higher among
African Americans than whites, the differential rates
between the two groups declined between 1997 and
2001.  Declining differences are due to consistent
decreases in STI rates in African Americans together
with an increase in STI rates in whites (U.S.  Trends
in Sexually Transmitted Diseases. [all from STD
Surveillance, 2001.  DHHS, CDC, September
2002 unless otherwise cited])
NIAID supports individual investigator-initiated
research grants and a variety of research programs
for the development of more effective prevention
and treatment approaches to control STIs
(www.niaid.nih.gov/dmid/STDs).  Research efforts
include developing and licensing vaccines, topical
microbicides, and treatments for the microbes that
cause STIs; understanding the long-term health
impact of sexually transmitted pathogens in various
populations; stimulating basic research on the
pathogenesis, immunity, and structural biology of
these pathogens; and developing better and more
rapid diagnostics.  Specific programs supported by
NIAID include the Sexually Transmitted Disease
(STD) Cooperative Research Centers (CRCs),
which bridge basic biomedical, clinical, behavioral,
and epidemiologic research; promote productive
collaborations among academic researchers; and
facilitate the development of intervention-oriented
research.  Another program, the STD Clinical Trials
Unit, conducts clinical trials to test the safety and
efficacy of biomedical and behavioral interventions
aimed at the prevention and control of STIs.
Finally, the Topical Microbicides Program Projects
conduct basic research, product development, and
clinical evaluation activities aimed at developing
female-controlled barrier methods for the
prevention of STIs and HIV/AIDS infection.
As part of the Public Health Service’s effort to
eliminate syphilis in the United States by 2005,
NIAID’s efforts focus on providing better
biomedical tools to prevent and control this disease.
These efforts include (1) diagnostic test
development, which is intended to create a rapid,
inexpensive, easy-to-use test that would not require
a blood sample; (2) a clinical research study of oral
therapy to treat early-stage syphilis; and (3)
development of a syphilis vaccine that would target
and prevent systemic infection (including congenital
syphilis) and could potentially ameliorate disease
progression.  
NIAID currently is supporting a clinical research
protocol examining a single oral dose of therapy for
early syphilis.  The goal of the study is to determine
whether treating syphilis with azithromycin is as
effective as the current recommended treatment,
benzathine penicillin G.  Azithromycin offers many
advantages over benzathine penicillin.
Azithromycin is taken orally; benzathine penicillin
is administered by often-painful injections that can
discourage patients from seeking treatment.
In addition, the penicillin injections require
refrigeration and needles, which can hamper
administration in “field” settings.  The azithromycin
regimen proposed in this study could be
administered as direct observed therapy in the field,
using strategies modeled after those used to treat
tuberculosis.  
The long-term goals of all NIAID’s syphilis
activities are to (1) complement CDC’s syphilis
elimination program, (2) provide improved
biomedical and behavioral tools to achieve and
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sustain syphilis elimination in the United States,
and (3) provide improved tools for prevention and
control of syphilis in developing countries.
NIAID’s research takes into account the limited
resources of areas where syphilis is endemic, the
social and cultural barriers to accessing effective
health care in some of those endemic areas, and the
need for sustainable interventions.
In addition, NIAID continues to initiate and
support a variety of other STI research projects,
including the following:
• Developing and evaluating STI diagnostics
designed for point-of-care use through the Small
Business Innovation Research mechanism
• Continuing to support grants for the development
of vaccines to prevent chlamydial and gonorrheal
infections
• Supporting a herpes vaccine efficacy trial
• Supporting an STD CRC focused on preventing
STIs.  Through this center, two studies will
examine strategies for preventing bacterial
vaginosis, herpes, and chlamydial infections
• Supporting an STD CRC focused on
multidisciplinary research on sexual behavior,
clinical epidemiology, immunobiology, and the
pathogenesis of gonococcal and chlamydial
infections
• Supporting an STD CRC that emphasizes
research exploring more effective interventions for
preventing STI morbidity in adolescents
• Supporting a longitudinal study to examine social
and sexual networks of Hispanic adolescents in
San Francisco
NIAID also supports the sequencing of the
genomes of sexually transmitted pathogens,
including Chlamydia trachomatis, Treponema
pallidum, and Ureaplasma urealyticum.  Completed
genome sequences have provided new insights into
the pathogenesis of their associated diseases and
pave the way for new opportunities to develop
diagnostics, drugs, vaccines, and microbicides.
Additional activities include the following: 
• Opened in November 2002, the Herpevac Trial
for Women is a pivotal phase III double-blind
clinical efficacy trial of an investigational vaccine
for the prevention of genital herpes.  The study,
conducted as a public-private partnership with
GlaxoSmithKline, will enroll 7,550 women at
approximately 25 sites across the United States.
The trial will require an estimated 4 years to
complete.
• This past year, the STDs Prevention Primate Unit
for preclinical evaluation of topical microbicides
and vaccines at the University of Washington
evaluated several candidate microbicides for safety
by examining the effects on surface tissues and the
impact on the microenvironment of the cervix
and vagina in pig-tailed macaques.  Results from
the testing contract are supported by the Division
of Microbiology and Infectious Diseases (DMID).
Coordination and testing are conducted in
association with the Division of Acquired
Immunodeficiency Syndrome (DAIDS).  DMID
and DAIDS will facilitate product development
and ensure safety and efficacy testing in clinical
trials.  
• The Topical Microbicides Development and
Evaluation Workshop, held on March 18–20,
2003, was the first joint meeting of DMID-,
DAIDS-, and NICHD-supported investigators
conducting research on topical microbicides.
The workshop addressed issues ranging from basic
research through formulation and applicator
design and served as a forum for establishing
collaborative work among STI and HIV/AIDS
investigators in the microbicide arena.
• The STD Clinical Trials Unit is conducting a
randomized phase III trial to evaluate the
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equivalency of oral azithromycin versus injectable
benzathine penicillin for the treatment of primary
syphilis.  If successful, this trial may provide an
additional antimicrobial strategy for treating
primary syphilis.  
• Collaborating with STD CRCs, NIAID continues
to support a research program with second-year
medical students from Howard University in
Washington, DC.  This program provides
students with a 10-week STI research experience
at the STD CRCs, with the long-term objective of
encouraging young minority physicians to pursue
careers in STI research.
Hepatitis C
Hepatitis C virus (HCV) infection is the most
common chronic blood-borne viral infection in the
United States.  HCV infects approximately 2 percent
of the U.S. population, or approximately 4 million
persons. New infections in the United States
continue at the rate of 25,000 cases per year
(www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm).
According to CDC, HCV infection occurs among
persons of all ages, but the highest incidence rate of
acute hepatitis C is found among persons between
ages 20 and 40 years, and males predominate.
African Americans and whites have similar
incidence rates of acute disease.  Persons of
Hispanic ethnicity have higher rates of acute
disease.  In the general population, the highest
prevalence rates of HCV infection are found among
persons in the 30-to-50 age range, and again males
predominate.  Unlike the rates of acute disease,
African Americans have a substantially higher
prevalence of HCV infection than do whites.
NIAID has aggressively pursued the expansion of
HCV research through its development of the
Hepatitis C Framework for Progress.  With the aid of
participating Institutes and Centers, an NIH-wide
framework was drafted that incorporates varying
individual missions into a cohesive global plan.  The
final plan underwent external review and has been
approved by the NIH Director as well as NIH
Institute and Center Directors.  The following
research goals were identified in the framework:
• Understanding HCV transmission modes to
develop effective intervention strategies
• Understanding HCV pathogenic mechanisms and
disease progression to develop effective treatments
• Characterizing hosts’ immune responses to HCV
infection to develop vaccines, prophylactic
measures, and therapeutic measures
• Defining viral replication and recovery with
therapy develop new therapeutic strategies
• Investigating clinical manifestations to develop
noninvasive methods to evaluate current disease
state, to predict outcomes, and to prevent or
reverse disease progression
• Defining effective prevention and intervention
strategies to improve health
One of the cornerstones of NIAID’s HCV effort is
the Hepatitis C Cooperative Research Centers (HC
CRCs), which were launched in 1996 as basic and
clinical research units devoted to understanding
HCV infection and disease processes.  Currently,
NIAID provides funding support to six HC CRCs.
The goals of NIAID’s six HC CRCs are to identify
components of HCV, isolate the body’s immune
response to HCV, determine the individual genetic
factors that have a crucial impact on recovery from
initial and chronic infection, track disease
progression and severity, and determine how
cofactors influence HCV disease.  Clinical research
emphasizes studies in special populations (e.g.,
African Americans) heavily affected by HCV that
respond poorly to standard therapies.  Specifically,
one of the HCV CRCs is conducting a therapeutic
clinical trial examining the use of pegylated
interferon and ribavirin in parallel cohorts of
African Americans and whites.  The goal of this
clinical trial is to determine what causes disparities
between African Americans and whites in response
to standard therapy.  
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Other NIAID HCV research activities include the
following:
• NIAID continues to provide partial support for
the ancillary studies of the NIDDK-sponsored
trial, “Hepatitis C Antiviral Long-term Treatment
against Cirrhosis (HALT-C).”  The trial is
evaluating the impact of long-term therapy on
disease progression, including virologic and
immunologic responses and their association with
recovery.
• NIAID supports HCV epidemiological research
and treatment trials within its HIV clinical trial
networks.
• NIAID research efforts toward the development of
vaccines have been and remain primarily focused
on developing a better understanding of the
molecular biology of HCV and the immune
response to HCV infection.  These investigations
are providing an in-depth analysis of immune
responses to HCV infection, the role of cytokines
and other immune regulatory molecules in the
control of HCV infections, and the evolution of
virus in response to the immune response
mounted by the host.  
• The development of antivirals for HCV has been
hindered by the lack of robust and economical
cell culture and animal models.  NIAID grantees
have recently developed a novel enzymatic
reporter system for the detection and quantitation
of HCV ribonucleic acid in intact cells.  This cell-
based system was optimized for a high-throughput
screening program and is being used to identify
new antiviral compounds for HCV.
• Extramural investigators developed HCV cell lines
that are now validated as in vitro antiviral
screening tools.  NIAID supports two of these
systems via its in vitro screening contract
programs.  These systems are used by academic
and corporate scientists (www.niaid.nih.gov/dmid/
viral).  
• NIAID’s extramural program has initiated two
activities to broaden HCV research and
development.  The first activity involves the
acquisition and provision of HCV research
reagents.  These reagents are obtainable through
the AIDS Research and Reference Reagent
Program (www.aidsreagent.org).  Other reagents
are available through www.niaid.nih.gov/reposit/
tetramer/index.html and www.bratonbiotech.com/
braton11.htm.  The second activity involves the
development of an annotated HCV sequence
database by Los Alamos National Laboratories
(http://hcv.lanl.gov/content/hcv-db/index).  
• NIAID released the “Liver and Pancreatic Disease
in HIV Infection” program announcement (PA),
sponsored jointly with NIDDK.  This program is
intended to stimulate research on the pathogenesis
and therapeutics of liver and pancreatic disease
associated with the co-infections (e.g., hepatitis B,
hepatitis C) that occur in patients with HIV
infection.  This PA also seeks to stimulate research
in the metabolic complications associated with
treating HIV infection.  Metabolic complications
include hepatic drug toxicity, hepatic lipid
metabolism, nonalcoholic steatohepatitis, and
pancreatitis.  
• Researchers supported by NIAID are investigating
the relationships between HCV replication,
evolution, and disease progression in Alaska
Natives.  To date, more than 900 HCV-positive
patients have been enrolled in the study.
Complete patient histories, including the
estimated date of infection and alcohol history, are
being obtained.  Blood and liver specimens are
being collected both retrospectively and
prospectively.  Specimens will be examined to
determine the levels and variation of HCV virus
and will be compared with the disease progression
in patients.  This well-defined Alaska Native
population may provide many key answers
regarding the natural history of hepatitis C and
may affect the future worldwide treatment of
hepatitis C.
Pneumonia
Pneumococcal pneumonia is an infection in the
lungs caused by the Streptococcus pneumoniae
(S. pneumoniae or pneumococcus).  Pneumococcus
Minorities and Biomedical Research
13
can infect the upper respiratory tracts of adults and
children and can spread to the blood, lungs, middle
ear, or nervous system.  More than 60,000 cases and
more than 6,000 deaths from invasive
pneumococcal disease (e.g., bacteremia and
meningitis) are estimated to occur annually in the
United States.  Rates of invasive infection increase
with age and are disproportionately higher among
certain minority populations.  For example,
children of Alaska Native ethnicity, those from
certain American Indian groups, and children of
African American origin have increased rates of
pneumococcal pneumonia.  Pneumococci account
for up to 36 percent of adult community-acquired
pneumonia and 50 percent of hospital-acquired
pneumonia.  Pneumonia is a common bacterial
complication of influenza and measles.  The
pneumonia case-fatality rate is 5 percent to
7 percent and may be much higher in elderly
persons (www.cdc.gov/nip/publications/pink/
pneumo2.pdf ).
NIAID has supported an efficacy and safety
phase III randomized trial in 8,292 Navajo and
White Mountain Apache children using the
licensed 7-valent pneumococcal conjugate vaccine
Prevnar.  Results of the trial demonstrate that the
vaccine is highly efficacious (76.8 percent) against
vaccine serotype invasive pneumococcal disease in
this high-risk population. The data clearly
demonstrate that the vaccine is capable of
preventing disease, not only in the general U.S.
population, but also in a setting where
pneumococcal colonization frequency is 50 percent
at 2 months of age.
Acquired Immunodeficiency Syndrome
Since the emergence of HIV/AIDS as a deadly
global infectious disease in 1981, considerable
progress has been made in understanding the
impact of HIV/AIDS on the immune system and
how to intervene therapeutically.  Researchers have
developed new techniques to detect HIV/AIDS in
blood and tissue and have also identified powerful
new antiviral therapies.  These therapies, referred to
as HAART, suppress the virus to undetectable levels
in the blood and delay disease progression and
death.  Since the widespread introduction of
HAART, deaths in persons with HIV/AIDS have
dropped dramatically in the United States and other
developed countries.  HIV-infected individuals live
longer as a result of HAART, but many experience a
host of complications from the complex therapeutic
regimen.  These complications include the
development of drug resistance, metabolic
abnormalities and toxicities, and patient
noncompliance.  Despite the scientific advances,
AIDS continues to rage around the world.  
According to the Joint United Nations Programme
on HIV/AIDS, 42 million people were estimated to
be living with HIV/AIDS, and 3.1 million people
died from AIDS worldwide in 2002.  In addition,
5 million people became infected with HIV in
2002, including 2 million women and 800,000
children aged 15 years and younger.
More than 830,000 cases of AIDS have been reported
in the United States since the epidemic began in
1981, with an estimated 384,906 persons known to
currently be living with AIDS.  One-quarter of the
approximately 950,000 Americans who currently may
be infected with HIV are unaware of their infection.
Although AIDS affects all groups, the disease
continues to disproportionately affect racial and
ethnic minority populations.  African Americans
and Hispanics constitute 61 percent of the AIDS
cases in the United States.  Although African
Americans comprise only 12 percent of the U.S.
population, they make up almost 41 percent of all
AIDS cases reported in the United States.  Similarly,
Hispanics comprise 13 percent of the U.S.
population and represent 19 percent of all AIDS
cases.  Of the new AIDS cases reported in 2002,
55 percent were among African Americans,
13 percent among Hispanics, and 32 percent
among whites; less than 1 percent were among
American Indians, Alaska Natives, and Asian-
Pacific Islanders. Among women, African
Americans and Hispanics account for 81 percent of
AIDS cases. Among men, African Americans and
Hispanics account for 64 percent of cases.  Minority
children also are disproportionately affected by
AIDS.  Of the 92 pediatric AIDS cases reported in
2002, 89 percent (82) were in African American
and Hispanic children.  CDC reported 16,371
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deaths from AIDS in the United States in 2002, of
which 52.3 percent were African Americans,
18.7 percent were Hispanics, 27.8 percent were
whites, 0.6 percent were Asian-Pacific Islanders, and
0.4 percent were American Indians and Alaska
Natives (CDC.  HIV/AIDS Surveillance Report,
Vol.14, 2002.  www.cdc.gov/hiv/stats/hasr1402.htm).
The disproportionate impact of the HIV/AIDS
epidemic is seen more clearly by comparing the
rates of infection between specific groups.  Rates of
infection are defined as the number of cases per
100,000 people.  The rate of HIV/AIDS infection
is 5.9 among whites, 58.7 among African
Americans, 19.2 among Hispanics, 4.0 among
Asian-Pacific Islanders, and 8.5 among American
Indians and Alaska Natives.  
The estimated number of people living with AIDS
at the end of 2002 in 30 areas with confidential
name-based reporting show that HIV transmission
due to substance abuse continues to be a significant
factor in contributing to the spread of HIV/AIDS
in minority communities.  Data show that
24 percent of African American males and
23 percent of Hispanic males reported injection
drug use as a potential exposure route for
HIV/AIDS.  In contrast, only 10 percent of whites
reported injection drug use as a potential for
exposure.  Among women, injection drug use was
reported as a potential exposure route for
HIV/AIDS by approximately 24 percent of African
Americans, 26 percent of Hispanics, 17 percent of
Asian-Pacific Islanders, 36 percent of American
Indians and Alaska Natives, and 34 percent of
whites.  A large proportion of women become
infected with HIV/AIDS through sexual contact
with an injection drug user.  Of the HIV+ women
in the United States, more than 75 percent were
infected through heterosexual contact.  Another
factor contributing to the spread of HIV/AIDS in
minority communities is men having sex with men
(MSMs).  For both African American and Hispanic
males, MSM continues to be the leading exposure
method (CDC.  HIV/AIDS Surveillance Report,
Vol.14, 2002).  For the most up-to-date U.S.
HIV/AIDS statistics, please visit
www.cdc.gov/hiv/stats/ hasr1402.htm.  
As the HIV/AIDS epidemic continues to expand in
minority communities, enrolling minority patients
in HIV/AIDS clinical trials is particularly urgent so
that research results are applicable to all populations
affected by the disease.  People of minority
backgrounds face unique social, economic, and
medical issues when coping with the challenges
associated with HIV/AIDS infection, and therefore,
one of the greatest challenges facing HIV/AIDS
researchers today is the recruitment and retention of
minority patients for clinical trials.  To ensure that
enrollment reflects the national epidemic, NIAID
has taken strong steps to encourage minority
participation in clinical trials, natural history
studies, and prevention studies.  NIAID works with
communities to identify and overcome barriers to
participating in clinical trials.  Outreach is
accomplished by developing culturally sensitive
education materials and providing additional
resources (e.g., childcare, transportation) that are
necessary for enhancing participation by all
communities in NIAID-sponsored trials.  NIAID
also has taken a leadership role in involving
community representatives in local, national, and
international research activities.  Encouraging
community members to play an active role in all
aspects of research facilitates communication and
helps ensure that new HIV/AIDS treatment and
prevention strategies address areas of utmost
concern to those affected by the disease.  NIAID’s
HIV/AIDS clinical research networks provide
opportunities for community representatives to
participate in the research process through local,
national, and international Community Advisory
Boards.  In addition, NIAID recently released the
“Enrolling Women and Minorities in HIV/AIDS
Research Trials” program announcement.  This
program will fund innovative approaches to reach,
enroll, and retain women and racial/ethnic
minorities in HIV/AIDS research trials in the
United States.  Research trials will be conducted to
advance the body of scientific knowledge that will
improve the diagnosis, treatment, and development
of preventive strategies for women and minorities.  
NIAID directs a large therapeutic clinical trials
program consisting of three groups: the Adult AIDS
Clinical Trials Group (AACTG), the Pediatric AIDS
Clinical Trials Group (PACTG), and the Terry
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Beirn Community Programs for Clinical Research
on AIDS (CPCRA).  AACTG investigates
therapeutic interventions for HIV infection, AIDS,
and complications of HIV-associated immune
deficiency in adults (http://aactg.s-3.com).  PACTG
evaluates clinical interventions for treating HIV
infection and HIV-associated illnesses in neonates,
infants, children, adolescents, and pregnant women.
PACTG also researches approaches to prevent
mother-to-child transmission (MTCT) of HIV
(http://pactg.s-3.com).  CPCRA is a network of
community-based health centers and clinics that
support clinical research in community settings.
CPCRA conducts large, comparative studies that
evaluate therapies and treatment strategies for HIV
infection and HIV-associated illnesses (www.cpcra.
org).  AACTG, PACTG, and CPCRA strive to
ensure that a sufficient proportion of minority
individuals is enrolled in clinical trials.  In 2003,
7,699 and 2,984 participants were enrolled in
AACTG and PACTG studies, respectively.  In the
AACTG, 29 percent were African American,
18 percent Hispanic, 2 percent Asian-Pacific
Islander, and less than 1 percent American Indian
and Alaska Native.  In the PACTG, 57 percent were
African American, 28 percent Hispanic, and less
than 1 percent Asian-Pacific Islander, American
Indian, or Alaska Native.  Of the 3,513 patients
who were enrolled in CPCRA studies during
FY 2003, 46 percent were African American,
16 percent were Hispanic, 0.7 percent were Asian-
Pacific Islanders, and 0.5 percent were American
Indians and Alaska Natives (NIAID.  HIV
Infections in Minority Populations, August, 2003.
www.thebody.com/niaid/2003/minorities_hiv.html).
NIAID’s epidemiologic research explores the clinical
course and factors contributing to the transmission
of HIV/AIDS infection in a variety of populations.
NIAID supports several studies, including the
Women and Infants Transmission Study (WITS),
which targets inner-city women and their children;
the Women’s Interagency HIV/AIDS Study
(WIHS), which explores the clinical course of
HIV/AIDS infection in women with a focus on
minority women (http://statepiaps.jhsph.edu/wihs);
and the Multicenter AIDS Cohort Study (MACS),
a prospective, longitudinal study of HIV/AIDS
disease in homosexual and bisexual men
(http://statepi.jhsph.edu/macs/macs).  WIHS and
MACS are the two largest observational studies of
HIV/AIDS in women and homosexual or bisexual
men in the United States.  These studies have made
major contributions in understanding how HIV is
spread, understanding HIV disease and progression
to AIDS, and developing the most effective
methods for treating HIV/AIDS.  As of the
completion of the enrollment period, WIHS and
MACS have increased the study group size by
60 percent and added to the total number of
minority participants.  The expanded groups will
focus on contemporary questions regarding HIV
infection and treatment.  This year, MACS is
entering its 20th year of research while WIHS has
just completed its 10th year of research.  In 2003,
the enrollment of individuals from minority
communities in NIAID-supported epidemiology
cohorts was 23.3 percent in MACS, 85.1 percent in
WIHS, and 85.4 percent in WITS.  MACS is
co-funded by the National Cancer Institute (NCI)
and the National Heart Lung and Blood Institute.
WIHS is co-funded by NCI, NICHD, the National
Institute of Dental and Craniofacial Research, and
the National Institute on Drug Abuse (NIDA).
Vaccine Development
NIAID continues to support efforts to develop an
effective HIV vaccine for use around the world.
Established in 2000, the HIV Vaccine Trials
Network (HVTN) is a collaboration of domestic
and international clinical sites dedicated to
developing a preventive HIV vaccine.  Building on
the previous accomplishments of NIAID’s AIDS
Vaccine Evaluation Group and the HIV Network
for Prevention Trials (HIVNET), HVTN tests and
evaluates candidate vaccines in clinical trials.  There
are 18 sites in the United States and 13 sites
overseas, including sites in Africa, Asia, South
America, and the Caribbean.  HVTN’s global
capacity will allow for rapid expansion and the
ability to perform large-scale studies of suitable
vaccines as more vaccine candidates enter the
pipeline for testing and development.  In 2003,
13 percent of participants in U.S. HVTN studies
were African American, 4.2 percent were Hispanic,
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1.8 percent were Asian-Pacific Islander, and
1.0 percent were American Indian and Alaska
Native.  
Currently, HVTN is conducting six phase I and
two phase II clinical trials of candidate HIV
vaccines.  For more information about these trials,
please visit www.hvtn.org or www.aidsinfo.nih.gov.
The participation of international sites and the
involvement of ethnically diverse populations in
HVTN studies are critical components of NIAID’s
HIV/AIDS vaccine effort.  HVTN’s broad
participation allows researchers to design studies
that examine factors crucial to developing an
effective vaccine for use around the world.  These
factors include genetic background, nutritional
status, effects of co-infection, and access to health
care.  HVTN’s international capacity also facilitates
studies of the HIV/AIDS subtypes, which affect a
minority of the global population.  Studying
HIV/AIDS subtypes is an important aspect of
developing a vaccine that will protect individuals
from the various circulating strains of HIV/AIDS.  
In addition to conducting clinical studies, HVTN
develops community outreach programs to educate
people about HIV/AIDS and vaccine research.
Through outreach, HVTN seeks to encourage
participation in clinical trials and enroll a diverse
population, emphasizing the recruitment of
minorities and women.  
NIAID also is actively involved in educating the
public about HIV vaccine research and is currently
in year two of its HIV Vaccine Communications
Campaign.  Targeting at-risk populations, in
particular African Americans, Hispanics, and
MSMs, the NIAID HIV Vaccine Communications
Campaign is developing and implementing a
national education campaign to increase awareness
of and support for HIV vaccine research, especially
in at-risk populations.  To ensure that community
needs are considered, NIAID receives input and
guidance from the HIV Vaccine Communications
Steering Group, a group of representatives from the
community, Federal agencies, pharmaceutical
companies, and HIV vaccine advocacy groups.  A
key component of the campaign’s first year was to
engage individuals and organizations representing
target audiences and currently involved in
HIV/AIDS prevention and treatment efforts.
Roundtable discussions were held with leaders in
the African American and Hispanic communities to
refine strategies and engage participants in materials
development, outreach, and other activities.  As part
of the campaign, a qualitative, comprehensive
research effort was conducted including primary
research (e.g., 28 focus groups) and secondary
research.  This past year, a national survey was
completed that evaluated the attitudes and
knowledge of HIV vaccine research in the general
population, as well as in segmented groups of
African Americans, Hispanics, and MSMs.  Key
findings of the survey indicate that large numbers of
African Americans and Hispanics believe that a
secret HIV vaccine already exists.  The survey also
reveals that many African Americans and Hispanics
do not know that all vaccine trial volunteers are
HIV negative and there is no risk of contracting
HIV from the vaccines being tested.  The HIV
Vaccine Communications Campaign is working to
correct the misperceptions that exist regarding HIV
vaccine trials and, at the same time, provide general
information about HIV vaccine research to
minority communities.  In early 2003, funding will
be provided to community-based and national
organizations with strong ties to racial and ethnic
minority communities to support local and national
HIV vaccine research awareness activities, including
activities related to HIV Vaccine Awareness Day,
which is designated May 18 of each year.  In
addition, the campaign is conducting an ongoing
program aimed at educating minority media about
HIV vaccine research so that they can be better
prepared to report on key research findings.  For
more general information about HIV vaccine
research, please visit www.niaid.nih.gov/newsroom/
mayday/default.htm.
NIAID established the Dale and Betty Bumpers
Vaccine Research Center (VRC) at NIH in 2000.
This unique venture within the NIH intramural
research program uses national and international
collaborations with scientists in academic, clinical,
and industrial laboratories to conduct research
facilitating the rigorous pursuit of effective vaccines
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for AIDS and other human diseases.  Developing
AIDS vaccines is the highest priority of the center.
VRC employs a multidisciplinary approach,
integrating research from basic and clinical
immunology and virology into vaccine design and
production.  VRC activities target three main
priorities:  (1) basic research to establish
mechanisms of inducing long-lasting protective
immunity against HIV and other pathogens that
present special challenges to vaccine development;
(2) the conception, design, and preparation of
vaccine candidates for HIV and related viruses; and
(3) laboratory analysis, animal testing, and clinical
trials of vaccine candidates.  
VRC actively recruits volunteers to participate in
phase I clinical trials.  VRC seeks to increase
minority participation through a process of
outreach and education.  Recruiting participants
from diverse ethnic backgrounds will ensure that all
potential stakeholders are included in developing a
successful vaccine.
In November 2002, VRC launched a phase I
clinical study of a novel DNA vaccine directed at
the three most globally prevalent HIV subtypes, or
clades.  The vaccine incorporates HIV genetic
material from clades A, B and C, which cause about
90 percent of all HIV infections around the world.
This first multigene, multiclade HIV vaccine to
enter human trials marks an important milestone in
the search for a single vaccine targeting the U.S.
subtypes of HIV and for the clades causing the
global epidemic.  During the year-long first phase of
the trial, conducted at the NIH campus in
Bethesda, Maryland, VRC scientists will assess the
vaccine’s safety and determine whether the vaccine
induces any immune response.  Expanded tests
conducted through HVTN are planned for several
domestic sites, as well as sites in Haiti and South
Africa.  
Prevention
Preventing the transmission of HIV/AIDS is an
important aspect of HIV/AIDS research activities.
In an effort to reduce the worldwide spread of HIV,
NIAID established the HIV Prevention Trials
Network (HPTN) in 2000.  HPTN is a global
network of clinical trial sites with 9 sites in the
United States and 16 international sites in Africa,
Asia, Europe, and South America.  The network
explores a variety of nonvaccine prevention
strategies to reduce HIV/AIDS transmission, such
as testing and developing biomedical and behavioral
intervention programs.  Because HIV/AIDS is
transmitted through different routes in various
populations, developing a variety of HIV/AIDS
prevention strategies will have a significant impact
on reducing transmission rates and slowing the
worldwide spread of HIV/AIDS.  In 2003,
9.5 percent of participants in U.S. HPTN studies
were African American, 15 percent were Hispanic,
2.6 percent were Asian-Pacific Islander, and
0.7 percent were American Indian or Alaska Native.
Besides being sponsored by NIAID, HPTN is
co-sponsored by NICHD, NIDA, and the National
Institute of Mental Health.  
HPTN evolved from HIVNET, a program that
conducted phase I, II, and III clinical trials at U.S.
and international sites.  Building on HIVNET’s
many accomplishments, HPTN continues to
expand the multidisciplinary research agenda
established by HIVNET.  HIVNET’s
accomplishments include the discovery of
nevirapine as an effective, affordable drug for
preventing MTCT of HIV/AIDS in developing
countries, and the establishment of the initial safety
and acceptability of two new nondetergent
microbicides.
The HPTN scientific agenda is divided into the
following six main areas of research: 
• Evaluating biomedical approaches to prevent
MTCT of HIV
• Developing and evaluating topical microbicides to
prevent transmission of HIV
• Developing behavioral interventions to help
people reduce their risk of exposure to HIV
• Developing interventions to reduce HIV infection
resulting from substance use 
A Partnership for Health
18
• Evaluating programs to control or reduce STIs as
a means of decreasing the risk of acquiring and
transmitting HIV infection
• Evaluating the impact of antiretroviral therapies in
reducing the infectiousness of individuals infected
with HIV 
Educating communities about HIV/AIDS
prevention trials and building community trust has
been an important and crucial aspect of HPTN and
HVTN outreach.  HPTN invites community
members to participate in developing its scientific
agenda to promote information exchange and
ensure that social, cultural, and political values are
respected.  Community members discuss study
designs, recruitment plans, volunteer incentives,
informed consent requirements, risk-reduction
strategies, and research findings.  Each HPTN site
also has a community educator who assists
community members in understanding the science
of HIV/AIDS, research methods that will be used,
and the clinical trial process.  Community educators
build community trust by creating open forums
allowing for candid conversations about community
fears and concerns related to Government-
sponsored research.  For information regarding
HPTN studies, please visit www.hptn.org or
www.aidsinfo.nih.gov.  
For more information on HIV/AIDS clinical
trials, please visit www.aidsinfo.nih.gov or call 
1-800-448-0440.
NIAID Outreach Activities
Disseminating research results to the media, health
professionals, and the public is an important aspect
of NIAID’s mission.  Outreach activities include
producing and publicizing print, audiovisual, and
Web-based materials; distributing materials at
professional and community meetings; and
sponsoring workshops and conferences for
community health care providers and the public.
NIAID produces materials on allergic and
immunologic diseases, AIDS/HIV, sexually
transmitted infections, and potential illnesses
caused by agents of bioterrorism.  Press releases,
information sheets, and booklets are distributed
worldwide in response to more than 10,000
requests from people who contact NIAID each year.
For example, the TB educational booklets Learn
About Tuberculosis/Aprenda Sobre la Tuberculosis and
Learn About Tuberculosis Infection/Aprenda Sobre la
Infeccion de laTuberculosis remain popular and are
distributed in English and Spanish each year.  In
addition, the NIAID Web site is visited 1.5 million
times each month.  Hundreds of thousands of
inquirers request materials or download
information from the NIAID Web site each year
(www.niaid.nih.gov).
Expanding its outreach efforts, NIAID keeps more
than 400 voluntary and scientific organizations
updated about Institute activities.  Periodic e-mails
provide NIAID research news and information on
advances that specifically relate to an organization’s
research interests.  In addition, workshops on HIV
vaccine research were featured at the AIDS Vaccine
2002 conference, the Conference on Retroviruses
and Opportunistic Infections, the U.S. Conference
on AIDS, the National AIDS Treatment Advocates
Forum, the National Association of People With
AIDS Conference, and many other scientific and
community-oriented conferences.  NIAID provides
exhibit booths at scientific, health-related, and
student scientific organization meetings and
conferences where staff distribute materials about
allergic, immunologic, and infectious diseases.  Staff
members working in the booths also answer
questions about NIAID research and job
opportunities.  NIAID performs outreach at
conferences sponsored by the following
organizations: the American Academy of Allergy,
Asthma and Immunology; American Society for
Microbiology; American Indian Science and
Engineering Society; Hispanic Association of
Colleges and Universities; American Public Health
Association; Society for Advancement of Chicanos
and Native Americans; and Congressional Black
Caucus.  NIAID has also provided outreach at the
Annual Black Family Reunion, the Annual
Biomedical Research Conference for Minority
Students, and the National Conference on Blacks in
Higher Education.
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NIAID has been involved extensively in the
outreach efforts of the Dale and Betty Bumpers
VRC.  As VRC prepares for its second HIV vaccine
trial, NIAID is helping to construct community
partnerships by targeting local news media, visiting
local churches and other community organizations,
and attending HIV/AIDS-related conferences and
meetings.
Working directly with the public is one aspect of
NIAID’s outreach campaign.  NIAID offers a
public-speaking component consisting of researchers
who will speak on request to community groups
and at public schools.  NIAID also has participated
in a community awareness program addressing
cancer awareness, self-management techniques for
asthma sufferers, and the silent damage done to the
body by hypertension.  Staff members have
participated as judges in science fair projects at local
schools.  Working in local schools provides NIAID
staff with the opportunity to interact with teachers,
parents, and budding scientists.
In FY 2003, NIAID held its first Health Disparities
Symposium titled “Increasing Diversity in Clinical
Trials: Best Practices.”  The symposium objectives
were the following:
• Examine cultural issues that affect the recruitment
and retention of minority participants in clinical
trials
• Provide researchers, outreach workers, and
community educators with effective strategies for
outreach, recruiting, and retaining participants
from minority populations
• Demonstrate best practices for using electronic
resources to identify applicable clinical trials,
human subjects policies, and funding sources and
mechanisms
The 200 symposium attendees included NIAID
grantees, members of advocacy groups, community
physicians, nurse practitioners, and research
clinicians.  The proceedings of the symposium will
be posted on the NIAID Web site at a future date.
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NIH-Wide Programs
Minority Biomedical Research Support Program
Through innovative programs and outreach efforts,
NIH continually works to increase the number of
minority researchers in the field of biomedical
research.  The Minority Biomedical Research
Support Program (MBRS) is one of the largest NIH
programs working toward this goal.  MBRS awards
grants to educational institutions with substantial
minority enrollment.  Grants are given to support
faculty research, strengthen an institution’s
biomedical research capabilities, and increase the
interest, skills, and competitiveness of students and
faculty in the pursuit of careers in biomedical
research.  NIH Institutes contribute money to the
National Institute of General Medical Sciences
(NIGMS), which administers MBRS through its
Division of Minority Opportunities in Research
(www.nigms.nih.gov/about_nigms/more.
html#mbrs).
A recent reorganization of MBRS raised the number
of institutions that are eligible for research and
institutional development support because of their
substantial minority student enrollment.  Along
with this increase, there also has been a rise in the
average size of requested grant awards, making these
grants comparable in size to other NIH research
grants.  There are three subcomponents of MBRS:
the Support of Continuous Research Excellence
(SCORE) initiative, the Research Initiative for
Scientific Enhancement (RISE), and the Initiative
for Minority Student Development (IMSD).
Collectively, SCORE, RISE, and IMSD provide
support from the undergraduate level to the
postdoctoral level in institutional development,
student and faculty training, and student and
faculty career development.  Overall program goals
for SCORE, RISE, and IMSD are to enhance the
science curricula and faculty research capabilities at
institutions with significant underrepresented
minority enrollment, encourage minority students
to pursue training for scientific careers, and
strengthen the research skills of minority students
and faculty.  The opportunities provided by these
programs encourage participation from institutions
ranging from 2-year colleges to research-intensive
institutions with doctoral programs.
SCORE provides financial assistance to competitive
research programs in all areas of biomedical and
behavioral research.  Funding is provided to develop
biomedical research faculty committed to improving
competitive research programs and increasing the
number of underrepresented minorities
professionally engaged in biomedical research.  The
program supports faculty-initiated, scientifically
meritorious research projects, including pilot
research projects (http://grants1.nih.gov/grants/
guide/pa-files/PAR-04-001.html).
RISE seeks to enhance the research environment at
minority-serving institutions through faculty and
student development by increasing the interests,
skills, and competitiveness of students and faculty
who are pursuing biomedical research careers.  RISE
offers support for faculty and student development
activities such as on-campus workshops, off-campus
workshops, specialty courses, travel to scientific
meetings, and research experiences at on-campus or
off-campus laboratories.  Support also is available
for evaluation activities and limited institutional
development (e.g., equipment purchases, the
development of research courses, the renovation or
remodeling of existing facilities to provide space for
an investigator to conduct developmental activities)
(http://grants.nih.gov/grants/guide/pa-files/PAR-99-
151.html).
IMSD encourages domestic private and public
educational institutions with fully developed and
funded research programs to initiate and/or expand
innovative programs to target underrepresented
minority students.  Institutions that receive the
funding are expected to improve the academic and
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II.  Minority Researchers’ Training and
Enhancement Programs
research capabilities of underrepresented minority
students and to facilitate their progress toward
careers in biomedical research.  Funding also may
be directed toward developing underrepresented
minority scientists who are in any phase of their
career development, from the undergraduate level
through the Ph.D. level.  IMSD awards use the
institutional education project grant mechanism
(http://grants1.nih.gov/grants/guide/pa-files/PAR-
02-084.html).
Minority Access to Research Careers
The Minority Access to Research Careers (MARC)
Undergraduate Student Training in Academic
Research (U*STAR) program provides support for
students who are members of minority groups that
are underrepresented in the biomedical sciences at
institutions with significant minority student
enrollments.  U*STAR seeks to improve students’
preparation for graduate training in biomedical
research through faculty development,
strengthening of science course curricula,
development of biomedical research training
programs, and infrastructure development.
Additional information about this program is
available online at http://grants1.nih.gov/grants/
guide/pa-files/PAR-02-033.html.
MARC predoctoral fellowships provide funding for
graduates of the U*STAR program.  The program
provides outstanding U*STAR students with up to
5 years of support for research training leading to a
Ph.D., M.D./Ph.D., or other combined professional
degree/Ph.D. in the biomedical or behavioral
sciences, including mathematics.  Support is
available only for individuals enrolled in a
combined professional degree/Ph.D. program in the
biomedical or behavioral sciences.  The MARC
predoctoral fellowship program encourages students
from minority groups underrepresented in the
biomedical and behavioral sciences to seek graduate
degrees.  This program furthers the NIH goal of
increasing the number of underrepresented minority
scientists who are competitively trained to pursue
careers in biomedical or behavioral research.  For
more details on these fellowships, visit
http://grants2.nih.gov/grants/guide/pa-files/PAR-
03-114.html.
MARC faculty predoctoral fellowships are awarded
to faculty members of colleges or universities with
significant minority enrollment.  Awards provide
eligible faculty lacking a Ph.D. degree or Ph.D.
equivalent the opportunity to obtain a research
doctorate.  Applicants must be full-time, permanent
faculty in a biomedical science or mathematics
program and must have been at the minority
institution for at least 3 years at the time of
application.  Candidates must be enrolled in or
have been accepted into a Ph.D. or combined
M.D./Ph.D. training program in the biomedical or
behavioral sciences at the time of application.
Applicants also must state their intention to return
to the minority institution at the end of their
training period.  Additional information on faculty
predoctoral fellowships is available at http://grants2.
nih.gov/grants/guide/pa-files/PAR-03-048.html.
MARC faculty senior fellowships are awarded to
eligible faculty members of colleges or universities
with significant minority enrollment.  The goal of
the fellowship is to provide eligible faculty members
a yearlong period of intensive research in a state-of-
the-art research environment to update their
research skills or move into new areas of research.
Applicants must be full-time faculty members in a
biomedical science or mathematics program for at
least 3 years at the time of application.  Moreover,
candidates must have received a Ph.D. or Ph.D.
equivalent at least 7 years before the date of
application.  Candidates must state their intention
to return to the minority institution at the end of
their training period.  Applicants must request
support ranging from 1 academic year (e.g.,
9 months) to 2 years.  Additional information is
available online at http://grants1.nih.gov/grants/
guide/pa-files/PAR-02-145.html.
Research Supplements for Underrepresented
Minorities Program
In 1989, NIH launched an initiative to provide
funding for underrepresented minorities in
biomedical research at all levels of career
development.  The Research Supplements for
Underrepresented Minorities (RSUM) program
seeks to increase the number of underrepresented
minorities in biomedical research.  RSUM
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accomplishes its mission by supplementing research
grants currently funded by NIH Institutes and
Centers.  Investigators with an existing NIH grant
may apply for supplemental funds from RSUM to
support minority high school, college, postgraduate,
postdoctoral, or junior faculty researchers to work
in an area closely allied to the funded research.
Awards may be tied to the length of the parent
grant and are limited to a total award period not to
exceed 4 years.
RSUM defines underrepresented minorities as
African Americans, Hispanics, American Indians
and Alaska Natives, and Asian-Pacific Islanders.
Funds are provided for salary, tuition, fees,
expendable supplies, travel, and other incidentals.
Award levels are determined by the targeted
educational strata, with smaller awards made to
high school students.  Salary stipends depend on
the level of experience and are consistent with the
salary scales provided to investigators at the same
level of experience in the grantee institution.
In fiscal year (FY) 2003, NIAID funded 41 new
and continuing RSUM applications for a total of
6 million dollars.  Awardees included minority
investigators at the junior faculty, postdoctoral,
predoctoral, undergraduate, and high school levels.
RSUM promises to be a continued success in
increasing the total number of underrepresented
minorities in biomedical research in areas of science
relevant to NIAID’s mission.  For more
information, please visit www.niaid.nih.gov/facts/
mwhhp5.htm#C.
Research Centers in Minority Institutions
NIAID continues to work toward its goal to expand
the national capability for health sciences research
through the Research Centers in Minority
Institutions (RCMI) program.  RCMI provides
grant support to predominantly minority health
professional schools and graduate institutions that
offer a doctorate in the health professions or 
health-related sciences.  The program assists
institutions in strengthening and augmenting their
human and physical resources for conducting
biomedical or behavioral research.  RCMI also
fosters faculty expansion and development,
infrastructure improvement, and the support of
research-related activities, including laboratory
renovation and equipment replacement.  Through
RCMI, institutions become more competitive in
seeking funding for biomedical or behavioral
research.  Institutions that qualify to receive RCMI
support must have more than 50-percent minority
student enrollment and be chartered to award
M.D., D.V.M., D.D.S., or Ph.D. health science
degrees.  Currently, 17 institutions participate in the
RCMI program.
RCMI’s HIV/AIDS Infrastructure Initiative seeks to
ensure that minority institutions have the physical
facilities and faculty competence to participate in
mainstream HIV/AIDS research.  Support is
awarded to expand physical infrastructure and
improve faculty competence in virology,
immunology, molecular biology, and the
neurosciences.  Participating institutions are located
in communities in which the HIV/AIDS epidemic
has hit the hardest.  As a result, these institutions
are uniquely suited to treat and recruit patients in
clinical trials.  Nine minority medical schools are
eligible to participate in the HIV/AIDS
Infrastructure Initiative:  Howard University,
Meharry Medical College, Morehouse School of
Medicine, University of Puerto Rico Medical
Sciences, Morgan State University, Universidad
Central del Caribe, Ponce School of Medicine,
Charles R. Drew School of Medicine and Science,
Texas Southern University, University of Hawaii,
and City University of New York.  
RCMI is co-funded by NIAID and the National
Center for Research Resources.  NIAID provides
support for RCMI HIV/AIDS research pilot
projects, as well as support for infrastructure
development.  In FY 2003, NIAID awarded pilot
projects for clinical research, molecular vaccine
development, opportunistic infections, and
immunologic research to seven institutions.
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NIAID Programs
Office of Special Populations and Research
Training
The Office of Special Populations and Research
Training (OSPRT) was established by NIAID’s
director in 1998 to combine the functions formerly
housed in the Office of Research on Minority and
Women’s Health (ORMWH) and the Office of
Science Training and Manpower Development
(OSTMD).  Combining the functions of OSTMD
and ORMWH under one entity has led to greater
efficiency in developing research and training
initiatives.  OSPRT administers the Introduction to
Biomedical Research Program (IBRP) and the
Bridging the Career Gap for Underrepresented
Minority Scientists workshop and serves as NIAID’s
coordinator and liaison for the Institute’s Strategic
Plan for Addressing Health Disparities.  In addition,
OSPRT plays a key role in reporting data about
women and minority inclusion in phase III clinical
trials.  
OSPRT’s director has been instrumental in
overseeing collaborative funding efforts between
NIAID, the Center for Minority Health and Health
Disparities, and the Office of Research on Women’s
Health.  OSPRT supports innovative programs,
such as the Inter-American College of Physicians
and Scientists, National Hispanic Youth Initiative,
and the Temple University Longitudinal Program.
Bridging the Career Gap
To increase the number of underrepresented
minority investigators in biomedical research, the
Bridging the Career Gap for Underrepresented
Minority Students initiative was established in
1993.  Targeting individuals who receive NIAID
minority training and research supplemental awards,
Bridging the Career Gap seeks to provide young,
minority investigators with the tools and
information needed for a successful career in
biomedical research.  The initiative consists of a 
2-day seminar addressing career choices,
networking, the importance of selecting the right
mentor, and the NIH grant system and
components.  The seminar also provides
participants with the opportunity to network with
NIAID intramural and extramural staff.  NIAID
staff continue to work closely with many students
throughout various phases of their careers.  The
Bridging the Career Gap program demonstrates
NIAID’s interest in the academic future of its
minority training and research supplemental
funding awardees.  NIAID continues to develop
innovative programs that will attract
underrepresented minority scientists to the
Institute’s research agenda.
Results from NIAID’s 1996 evaluation of the first
two Bridging the Career Gap program cohorts
illustrate the program’s success.  Survey results show
that the seminar has many benefits including
helping participants understand what to expect
from careers in biomedical research and assisting
individuals to determine what adjustments are
needed in their current career direction to pursue
futures in biomedical research; it also provides
participants with the opportunity to establish
important NIAID contacts.  The success of
NIAID’s Bridging the Career Gap program also has
been validated through its replication in other NIH
Institutes.  The program is administered by OSPRT
and is conducted with the assistance of NIAID
scientific review, program, and grants management
staff and with scientific and administrative experts
from academia and industry aligned with NIAID.
The sixth Bridging the Career Gap symposium was
held in November 2003 and was attended by 70
individuals.  
Centers for AIDS Research 
NIAID promotes the development of minority
scientists in HIV/AIDS research through Centers
for AIDS Research (CFARs).  CFARs support a
multidisciplinary environment promoting basic,
clinical, behavioral, and translational research in the
prevention, detection, and treatment of HIV/AIDS
infections.  CFARs accomplish their mission
through outreach, fostering scientific
communication, training, and sponsoring
education.  NIAID-sponsored CFARs are
committed to educating and training minority
A Partnership for Health
24
Minorities and Biomedical Research
25
investigators, as well as providing outreach to
minority communities.  
NIAID Enhancement Award
Historically, NIAID has supported a variety of
programs seeking to encourage underrepresented
minority investigators to pursue careers in
biomedical research.  Programs have targeted
students ranging in age from high school to
postdoctoral levels, and, although these programs
have demonstrated success in specific areas, only a
few underrepresented minority investigators have
become well established in biomedical research.
The NIAID Enhancement Award for
Underrepresented Minorities was established in
FY 2003 to recruit talented underrepresented
minority investigators in the early stages of their
scientific careers (e.g., assistant professor or junior-
level faculty) for basic or clinical research programs
in the areas of allergy, immunology, transplantation,
microbiology, and infectious diseases, including
AIDS.  The present Request for Applications is
intended to increase the number of
underrepresented minority investigators capable of
performing independent competitive research and
to enhance the long-term research skills and
potential of these individuals in all of NIAID’s
scientific research areas.  For more information,
please look on the Web at http://grants1.nih.gov/
grants/guide/rfa-files/RFA-AI-03-045.html.
NIAID/Mali Medical School Minority Training
Initiative
In early 1997, the NIAID Division of Intramural
Research (DIR), the University of Mali Medical
School, and the University of Maryland School of
Medicine created a program to provide training
opportunities for minority students and young
faculty in Africa.  NIAID/Mali Medical School
Minority Training initiative seeks to provide
opportunities that will attract minority students and
young faculty to careers in tropical medicine.  As a
part of the program, American students train in
malarial research under Malian researchers at the
Malaria Research and Training Center (MRTC) in
Bamako, Mali.  In turn, Malian researchers are
given sabbaticals to learn new research techniques at
NIAID.  
In December 1998, the Guest House, located on
the campus of the National School of Medicine of
Mali and immediately adjacent to MRTC
laboratories and the National Medical Library of
Mali, was completed.  Consisting of a living room,
dining, room, kitchen, computer room/library, and
eight bedrooms, the Guest House serves as the base
of operations for the training program.  Each
bedroom is equipped with its own computer while
the computer room/library has two computers
linked to the medical school local area network and
the Internet.  To ensure student safety, the Guest
House is situated within the medical school
complex and surrounded by an additional wall
staffed by a night guard.  Although Mali is generally
considered one of the safest countries in Africa, the
routine safety precautions are in place to reassure
parents and students.
MRTC provides an intricate training program that
can accommodate the various educational levels of
student participants (e.g., advanced undergraduate
students, graduate students, postdoctoral fellows,
junior faculty, midcareer faculty) with a potential
interest in tropical medicine research.  Medical
students, recent medical graduates, junior medical
faculty, and midcareer faculty are given the
opportunity to participate in medical school field
training programs, laboratory work, and field work.  
The training program emphasizes field research and
provides opportunities for all students to work in
local villages.  As NIH prepares Mali to be a major
test site for malaria vaccines, MRTC program
participants will have an opportunity to take part in
this important and exciting initiative.
In May 1998, the University of Maryland School of
Medicine received funding through the Fogarty
International Center to manage the promotion,
recruitment, selection, and posting of students and
fellows in Mali.  In FY 2003, a total of 10 students
were enrolled in the program, including 2 African
Americans, 5 whites, and 3 Asian-Pacific Islanders.  
Introduction to Biomedical Research Program
The NIAID IBRP was established in 1979 to
inform academically talented college juniors,
graduating seniors, and first-year graduate or
medical students from underrepresented minority
groups about career opportunities in the broad field
of biomedical research.  This initiative grew out of
the need to increase the number of minority
scientific researchers in this country.  While the
numbers of underrepresented minorities in the life
sciences has increased, their numbers are still small;
to meet the continuing challenge of attracting this
population, the program was divided into two
distinct programs in 2003.  The Richard M.
Asofsky Scholars In Research (ASIR) is the IBRP
extramural arm and is administered through
OSPRT.  The intramural arm of IBRP is known as
the Introduction to NIAID Research Opportunities
(INRO) and is administered through the Division
of Intramural Research’s Office of Special Emphasis.
For more information, please visit
www.niaid.nih.gov/ibrp.
Richard M. Asofsky Scholars In Research 
For 37 years, Dr. Richard M. Asofsky served NIH
and NIAID in improving research training
programs.  The ASIR program was created in honor
of Dr. Asofsky to bring underrepresented minorities
into the biomedical sciences.  ASIR provides
supplemental funding to NIAID extramural
principal investigators to conduct laboratory
research with underrepresented minority high
school and college students.  Students gain a
mentoring relationship and are exposed to research
career opportunities in the areas of allergy,
immunology, transplantation, microbiology, and
infectious diseases, including AIDS.  In FY 2003,
19 students were supported by five NIAID grantees.  
Intramural NIAID Research Opportunities
Program 
Recently, NIAID’s Office of Special Emphasis
Programs launched the INRO program to
encourage committed and talented
underrepresented minority students to consider
careers in allergy, immunology, and infectious
disease research.  Undergraduate and first-year
graduate students with a GPA of 3.5 or better were
selected to participate in the program based on their
interest in NIAID research and their desire to
conduct research at the NIH.  To qualify for the
program, applicants also must be American citizens
or legal U.S. residents.  In FY 2003, 12 students
attended the 3-day intramural program representing
colleges and universities from across the United
States, Puerto Rico, and the U.S. Virgin Islands.
The 3-day program focused on the breadth of
research conducted at NIAID and included
scientific lectures by intramural researchers,
discussions with scientists, and tours of the
laboratories in the Research Technology Branch and
the Vaccine Research Center.  Students also
discussed training opportunities with scientists who
conduct research in Rockville, Maryland, and the
Rocky Mountain Laboratories in Hamilton,
Montana.  For more information, please visit
www.niaid.nih.gov/dir/inro/default.htm.
Temple University Longitudinal Program
In FY 2001, NIAID collaborated with the National
Institute of Diabetes and Digestive and Kidney
Diseases and the National Institute of Arthritis and
Musculoskeletal and Skin Diseases to establish the
Temple University Minority Access to Biomedical
Research Careers initiative at Temple University in
Philadelphia.  The initiative is a longitudinal
program that recruits outstanding middle school
students and provides them with additional
instruction in mathematics and the sciences.  The
goal of this initiative is to increase the pool of
M.D./Ph.D. program applicants by ensuring that
students succeed in high school and continue in
their education to obtain graduate degrees.
Participating students are extremely motivated,
have research experience, and have very strong
academic records.  During the summer of their
junior and senior years of high school, participants
are placed in NIAID intramural laboratories for an
8-week rotation.  When participants enter college,
the 9-week summer experiences are rotated among
Federal, private, and academic institutions.  
Participating students assist in research projects, and
many of them have been cited in research
publications.  In FY 2002, 207 students were
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participating: 148 African Americans, 32 Asians-
Pacific Islanders, and 27 Hispanics.  NIAID will
continue to support this initiative through FY 2005.  
Partnership Program
The Partnership Program continues to benefit
NIAID and participating schools.  As part of the
Partners in Education Program, students are
exposed to a scientific environment and are given
the opportunity to see science in action, meet and
consult with working scientists, gain practical
experience by participating in laboratory work, and
receive supplemental instruction.  Students’ interests
in the sciences are nurtured through the education
program as they improve their understanding and
knowledge of biomedical research.  Additional
resources include monthly lectures, mentoring, role
models, tutorial matching, library resources,
incentive awards, workplace tours, faculty
enrichment, and advisory services.  Participating
schools also have received NIAID-donated
computers, fax machines, microscopes, and
numerous laboratory supplies for their science
classrooms.
Six schools participated in the Partnership Program
in FY 2003.  NIAID has partnership agreements
with three high schools and three elementary
schools: Dunbar High, Friendly High, Crossland
High, Ideal Academy, St. Thomas More, and
Carmody Hills.
Biomedical Research After School Scholars
Since 1998, scientists from NIAID’s Rocky
Mountain Laboratories (RML) in Hamilton,
Montana, have teamed up with local middle and
high schools to present the Biomedical Research
After School Scholars (BRASS) program.  BRASS
introduces 7th- through 12th-grade students to the
fundamentals and relevance of biomedical research
to stimulate student interest in science and
encourage students to pursue careers in biomedical
research.  The program encourages a broad range of
student participation, from minorities, young
women, economically disadvantaged, and at-risk
students.  
BRASS consists of five 2-hour laboratory sessions
covering hematology, genetics, cancer, infectious
diseases, and animal research.  Each 2-hour session
is highly interactive, with scientists providing
background on topics using the scientific method.
The program concludes with a commencement
ceremony featuring a guest speaker and laboratory
demonstrations conducted by the students.
More than 60 scientists and 350 students have
participated BRASS.  RML scientists have worked
with middle schools in Montana, including
Hamilton, Corvallis, Victor, Darby, Stevensville,
and Lone Rock middle schools.  A March 2003
regional newspaper article, written by students from
Lone Rock middle school, can be found at
www.missoulian.com/articles/2003/03/17/
export3781.txt.
In 2000, RML expanded BRASS to schools located
in American Indian and Alaska Native
communities.  During the past 3 summers, 45
scientists have participated in the Pathways to
Academic Excellence (PACE), a mini-BRASS
program at an American Indian and Alaska Native
summer math and science camp.  More than 150
American Indian and Alaska Native students have
participated in the minicourse.  
Collaborative Efforts
Native American Research Centers for Health
In FY 2001, NIGMS and the Indian Health Service
developed the Native American Research Centers
for Health (NARCH) program.  NARCH supports
the development of partnerships composed of
American Indian and Alaska Native tribes or
tribal-based organizations (e.g., the National Indian
Health Board, Local Area Health Boards) and
institutions conducting intensive, academic-level,
biomedical and behavioral research.  The purpose of
NARCH is to (1) encourage competitive research
linked to reducing health disparities, (2) develop a
cadre of American Indian and Alaska Native
scientists and health professionals engaged in
biomedical, clinical, and behavioral research who
will be able to compete for NIH funding,
(3) increase the collaborative efforts of research-
intensive institutions and American Indian and
Alaska Native organizations and (4) reduce
American Indian and Alaska Native community
skepticism toward Government-funded research.
NARCH continues to support research, student
development, and faculty development projects.  
As a part of NARCH, NIAID supports two studies
that will investigate adult pneumococcal infections
in Alaska Natives and White Mountain Apaches.
Support for these two studies will continue through
FY 2005 and is anticipated to continue through
FY 2006.
Interamerican College of Physicians and
Scientists 
Increasing the participation of underrepresented
minority investigators in virtually all fields of
biomedical research is a continuing NIH and
NIAID priority.  NIAID supports a variety of
minority programs for biomedical research, from
high school through postdoctoral training.
NIAID’s OSPRT is engaged in an extensive
outreach campaign targeting colleges, universities,
medical centers, and professional organizations to
encourage the participation of minority
investigators in NIAID research activities.  The
Interamerican College of Physicians and Scientists
(ICPS) is one outreach activity supported by
OSPRT that targets a specific underrepresented
community.  Founded in 1979, OSPRT promotes
cooperation among U.S. Hispanic physicians and
seeks to advance their professional and educational
development.  ICPS is the only national
organization representing Hispanic physicians.  
The official ICPS journal, MEDICO Interamericano,
is distributed monthly to 39,000 physicians in the
United States.  MEDICO Interamericano provides
information on grants and contracts, as well as
information on professional opportunities for
Hispanics in academia, Government agencies, and
the private sector.  ICPS outreach capabilities help
increase Hispanic student participation in biomedical
research, educate communities regarding minority
health issues, and explain NIAID’s role in addressing
minority health issues through research and other
activities.  NIAID continues to provide funding to
the ICPS National Hispanic Youth Initiative in
Health (NHYI) summer program.  NHYI introduces
Hispanic youth to careers in biomedical research
through scientific seminars and field trips.  NHYI
motivates, prepares, and encourages Hispanic high
school juniors and seniors to pursue careers in health
sciences.
Association of American Indian Physicians
National Native American Youth Initiative 
Through its cooperative agreement with the Office
of Minority Health, the Department of Health and
Human Services’ Association of American Indian
Physicians (AAIP) offers a health, biomedical
research, and policy development program for
American Indian and Alaska Native students
between ages 16 and 18 years.  AAIP seeks to
motivate American Indian and Alaska Native
students to remain in school and pursue careers in
health professions and/or biomedical research.  The
National Native American Youth Initiative (NNAYI)
prepares American Indian and Alaska Native
students for admission to college and professional
schools by empowering students with effective
leadership skills, analytical skills, and academic
proficiency.  Promoting self-awareness, NNAYI
educates students regarding health status, health care
research issues, and policies and legislation that affect
American Indian and Alaska Native communities.
NNAYI is an intense academic enrichment and
reinforcement program consisting of mini-block
courses addressing leadership, communication, study
skills, testing skills, assertiveness, networking,
professional behavior, interactive learning, and time
management.  Courses are designed to increase
students’ skills so they are better prepared to remain
in school and pursue a career in the health
professions and/or biomedical research.  The summer
program introduces students to the variety of health
careers available to American Indian and Alaska
Native youth.  AAIP members, health professionals,
and traditional healers provide a personal perspective
for students by relating their experiences in health
careers to their familiarity with collaborative efforts
between Western and traditional medicine.
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Allergy, Immunology and
Transplantation
NIAID will continue to work toward meeting its
goals of increasing efforts in the areas of allergy,
immunology, and transplantation that target
minority populations and their health care.  These
plans include the following: 
• Through the Immune Tolerance Network and the
Autoimmunity Centers of Excellence, NIAID will
continue to support clinical trials and assay
development for promising tolerance induction
and immunomodulatory strategies to treat asthma
and allergic diseases; autoimmune diseases,
including systemic lupus erythematosus and
scleroderma; and rejection of transplanted organs,
tissues, and cells.
• The NIAID Inner-City Asthma Consortium will
launch three protocols in 2004, including a
cockroach allergen standardization protocol, a
study to evaluate the usefulness of measuring
exhaled nitric oxide in the clinical management of
asthma in children, and a birth cohort to
investigate factors that contribute to the
development of asthma in inner-city children.
• NIAID will sponsor a workshop at the 2004
annual meeting of the American Academy of
Asthma, Allergy and Immunology focusing on the
influence of allergens on asthma severity and
asthma interventions in inner-city children.
• NIAID plans to sponsor a symposium at the 2004
annual meeting of the American Thoracic Society
highlighting recent results of the NIAID National
Institute of Environmental Health Sciences’
Inner-City Asthma Study.
• In 2004, NIAID will launch the Clinical Trials in
Organ Transplantation program.  The new
program will support a cooperative, multisite
consortium for interventional or observational
clinical studies, accompanied by mechanistic
studies, to research the immune-mediated
pathologic processes in organ transplantation.
The consortium will work toward understanding
immune-mediated morbidity and mortality of
organ transplantation and will seek to develop
strategies that will reduce organ transplantation
morbidity and mortality.
• In 2004, NIAID will launch the Genomics of
Transplantation Program.  The new program will
establish cooperative interdisciplinary research
programs for large-scale, broad-scope genomic
studies in clinical transplantation, including solid
organ, tissue, and cell transplantation.  The goals
of this program are to identify and characterize
gene polymorphisms and gene expression patterns
in immune responses relating to the onset and
severity of acute and chronic graft rejection,
responses to immunosuppressive therapeutics, and
variability in graft survival among populations.
Microbiology and Infectious Diseases
NIAID plans to continue its multidisciplinary
microbiology and infectious disease strategies
through basic research, targeted studies, and
developing innovative vaccine delivery techniques
for diseases and infections that disproportionately
affect minority populations.  Support for
investigator-initiated research in areas related to
minority health will remain a priority.  Plans
include the following:
• Support for investigator-initiated, tuberculosis
(TB) basic and applied Mycobacterium tuberculosis
(M.tb) research will remain a priority.  NIAID
seeks to add to the fundamental base of
knowledge about M.Tb and the pathogenesis of
TB to develop improved diagnostic, therapeutic,
and intervention strategies for combating TB.
NIAID’s Division of Microbiology and Infectious
Diseases considers the development of improved
TB vaccines, drugs, and diagnostics a high
priority.
III.  Future Plans
• NIAID’s Division of AIDS will continue to
support research to discover new, more effective,
selective therapeutic agents to treat and prevent
TB through screening contracts, investigator-
initiated grants, the National Cooperative Drug
Discovery Groups for the Treatment of
Opportunistic Infections Associated with AIDS
program, and Small Business Innovation
Research/Small Business Technology Transfer
mechanisms.
• NIAID will continue funding basic and clinical
research studies on mechanisms of pathogenesis
and immunology of bacterial and viral sexually
transmitted infections.
• NIAID will continue to support investigator-
initiated basic and clinical research for hepatitis C
virus.  Multidisciplinary research approaches will
be encouraged.
• NIAID is exploring the possibility of developing
diagnostic assays that can quickly differentiate
between bacterial and viral respiratory infections.
NIAID also is exploring the possibility of
identifying the virulence genes associated with
lung tissue that can specifically recognize
pneumococcal infections using sputum samples.
• NIAID continues to support efforts to examine
new, alternative approaches for improving the
diagnosis of community-acquired pneumonia.
Acquired Immunodeficiency Syndrome
NIAID will continue developing innovative
strategies to augment minority participation in
HIV/AIDS clinical trials and epidemiologic studies.
Encouraging the participation of minority
investigators in all facets of basic and clinical
HIV/AIDS research remains a high priority for
NIAID.  Specific plans include the following:
• NIAID will continue to co-fund meritorious,
peer-reviewed HIV/AIDS projects through the
HIV/AIDS Infrastructure Initiative of the
Research Centers in Minority Institutions
(RCMI) program.
• NIAID will continue to support grant
supplements to attract underrepresented minority
investigators into biomedical and behavioral
research through the Research Supplements for
Underrepresented Minorities (RSUM) program.  
• NIAID will continue to support the Adult and
Pediatric AIDS Clinical Trials Group, Terry Beirn
Community Programs for Clinical Research on
AIDS, HIV Vaccine Trials Network (HVTN) and
HIV Prevention Trials Network (HPTN).  Efforts
will continue to increase the participation of
women and underrepresented minorities in
HIV/AIDS clinical trials.  
• NIAID will continue to develop and implement
the HIV Vaccine Communications Campaign.  In
addition, NIAID will continue to coordinate
activities surrounding the observance of HIV
Vaccine Awareness Day on May 18.  Please visit
www.niaid.nih.gov/newsroom/mayday/default.ht
m for more information.
• NIAID will continue to fund the Centers for
AIDS Research program.
• NIAID will study the scope and relevance of viral
and human genetic variation in relation to vaccine
development through HVTN and collaborative
efforts with other scientists.
• NIAID will continue to fund the Multicenter
AIDS Cohort Study and the Women’s Interagency
HIV Study epidemiologic cohorts.
Training
NIAID will continue supporting training efforts
that encourage underrepresented minority
investigators to pursue careers in biomedical
research.  Specific plans include the following: 
• NIAID will continue to support the minority
training programs administered through National
Institute of General Medical Sciences.  
A Partnership for Health
30
Minorities and Biomedical Research
31
• NIAID will continue to fund the AIDS projects
conducted in the National Center for Research
Resources’ RCMI program.
• NIAID will continue to provide support for the
Richard M. Asofsky Scholars in Research
initiative.  NIAID expects to exceed 2003
successes in future years.  
• The Intramural NIAID Research Opportunities
(INRO) program will be expanded to 5 days in
2004.
• NIAID continues to support the Enhancement
Award for Underrepresented Minorities.  The
Enhancement Award initiative is expected to
make several additional awards in FY 2004.  
• NIAID will continue efforts to increase the
number of minority researchers supported by
RSUM.  A Bridging the Career Gap seminar will
be conducted in October 2005.  
• NIAID will explore new concepts and ideas to
improve outreach efforts to precollege students
and will continue to support educational efforts at
the middle and high school levels including the
Temple Longitudinal Program, the Partners in
Education Program, and Biomedical Research
After School Scholars.  
• NIAID will continue to actively recruit
underrepresented minority researchers.  
Outreach Activities
NIAID will continue its efforts to disseminate
research results to the media, health professionals,
and the public.  Specific outreach activities include
the following:
• NIAID will continue to implement innovative
activities designed to improve awareness of
biomedical research issues, awareness of clinical
trials, and interest in biomedical research in
underrepresented minority communities.  
• NIAID will continue to support programs that
increase the numbers of underrepresented
minority individuals who pursue careers in
biomedical research.  
• NIAID will continue its efforts to increase public
awareness of HIV vaccine and research and to
recruit diverse volunteers for future clinical
studies.
• NIAID will continue its outreach activities
including producing and publicizing print,
audiovisual, and Web-based materials; distributing
materials at professional and community
meetings; and sponsoring workshops and
conferences for community health care providers
and the public.
• NIAID will continue informing more than 400
voluntary and scientific organizations about
Institute activities.
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